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SCIENTIFIC OPINION 
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Alicyclic ketones and precursors from chemical subgroup 2.7 of FGE.19
1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
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2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate the genotoxic potential of 26 flavouring substances from subgroup 2.7 of 
FGE.19 in the Flavouring Group Evaluation 213. In the first version of FGE.213 the Panel concluded based on 
available genotoxicity data that a concern regarding genotoxicity could be ruled out for [FL-no: 07.047, 07.056, 
07.057, 07.075, 07.076, 07.080, 07.117, 07.118, 07.119, 07.120 and 07.168], but for the remaining 15 substances 
in subgroup 2.7 further genotoxicity data were required. Based on new submitted genotoxicity data, the Panel 
concluded in FGE.213Rev1 that the concern regarding genotoxicity could be ruled out for 13 substances in 
subgroup 2.7 [FL-no: 02.106, 07.008, 07.010, 07.041, 07.083, 07.089, 07.108, 07.109, 07.127, 07.136, 07.200, 
07.224 and 09.305] but not for maltol [FL-no: 07.014] and maltyl isobutyrate [FL-no: 09.525]. 
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SUMMARY 
The Scientific Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) is asked to advise the Commission on the implications for human health of chemically defined 
flavouring substances used in or on foodstuffs in the Member States. In particular, the Scientific Panel 
is asked to evaluate flavouring substances using the procedure as referred to in the Commission 
Regulation EC No 1565/2000.  
The present revision of FGE.213, FGE.213Rev1 is due to additional genotoxicity data submitted by 
the Industry in response to genotoxicity data requests presented in FGE.213. New genotoxicity studies 
have been submitted for the five substances beta-ionone [FL-no: 07.008], maltol [FL-no: 07.014], 
beta-damascone [FL-no: 07.083], nootkatone [FL-no: 07.089] and 2,6,6-trimethylcyclohex-2-en-1,4-
dione [FL-no: 07.109]. 
The Flavouring Group Evaluation 213 concerns 26 substances, corresponding to subgroup 2.7 of 
FGE.19. Twenty-three of the substances are α,β-unsaturated alicyclic ketones [FL-no: 07.008, 07.010, 
07.014, 07.041, 07.047, 07.056, 07.057, 07.075, 07.076, 07.080, 07.083, 07.089, 07.108, 07.109, 
07.117, 07.118, 07.119, 07.120, 07.127, 07.136, 07.168, 07.200 and 07.224] and three are precursors 
for such ketones [FL-no: 02.106, 09.305 and 09.525]. 
In the first version of FGE.213 the Panel concluded that the genotoxicity concern for ethyl maltol [FL-
no: 07.047], 3-ethylcyclopentan-1,2-dione [FL-no: 07.057] and the nine structurally related substances 
[FL-no: 07.117, 07.118, 07.119, 07.120, 07.056, 07.168, 07.075, 07.076 and 07.080] could be ruled 
out and the 11 substances could accordingly be evaluated through the Procedure. 
For maltol [FL-no: 07.014], a micronucleus assay after oral application was required in addition to an 
in vivo Comet assay in order to clarify the genotoxic potential. The outcome would also be applicable 
to maltyl isobutyrate [FL-no: 09.525]. 
The remaining 13 substances (including two precursors of a ketone) [FL-no: 02.106, 07.008, 07.010, 
07.041, 07.083, 07.089, 07.108, 07.109, 07.127, 07.136, 07.200, 07.224 and 09.305] could not be 
evaluated through the Procedure. Accordingly, additional data on genotoxicity were required for 
representatives of these 13 substances. 
The flavouring Industry has informed that it does not longer support the representative flavouring 
substance, piperitenone oxide [FL-no: 16.044], for which the Panel requested additional data. Since 
the previous version of the FGE, one additional substance has been included in subgroup 2.7, tr-1-
(2,6,6-Trimethyl-1-cyclohexen-1-yl)but-2-en-1-one [FL-no: 07.224], which is structurally related to 
the other substances for which the genotoxic potential could not be ruled out. 
In FGE.213Rev1 the Panel has evaluated the new data submitted by the Industry in response to the 
data request presented in FGE.213. Based on these new data the Panel concluded that the genotoxicity 
concern could be ruled out for the representative substances beta-ionone [FL-no: 07.008], beta-
damascone [FL-no: 07.083], nootkatone [FL-no: 07.089], 2,6,6-trimethylcyclohex-2-en-1,4-dione [FL-
no: 07.109] and the nine substances that they represent, being [FL-no: 02.106, 07.010, 07.041, 07.108, 
07.127, 07.136, 07.200, 07.224 and 09.305]. 
The Panel considered also the new data submitted for maltol [FL-no: 07.014] and concluded that for 
maltol [FL-no: 07.014] and maltyl isobutyrate [FL-no: 09.525] the concern for genotoxicity could not 
be ruled out. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavouring is regulated under Regulation (EC) No 1334/2008
4 of the European Parliament 
and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of article 9(a) of this Regulation an evaluation and 
approval are required for flavouring substances. 
The Union List of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012
5. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000
6. 
EFSA concluded that a genotoxic potential of 15 of the α,β-unsaturated alicyclic ketones and 
precursors in FGE.213 could not be ruled out.  
Information on four representative materials have now been submitted by the European Flavour   
Association. These are beta-ionone [FL-no: 07.008], maltol [FL-no: 07.014], nootkatone [FL-no: 
07.089] and 2,6,6-trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109]. 
This information is intended to cover also the re-evaluation of the following eight substances from 
FGE.19 subgroup 2.7: 
•  4-(2,6,6-trimethylcyclohexenyl)but-3-en-2-ol  [FL-no: 02.106] 
•  Methyl-beta-ionone [FL-no: 07.010] 
•  beta-Isomethylionone [FL-no: 07.041] 
•  p-Mentha-1,4(8)-dien-3-one [FL-no: 07.127] 
•  4,4a,5,6-Tetrahydro-7-methylnapthalen-2(3H)-one [FL-no: 07.136] 
•  4-(2,5,6,6-Tetramethyl-1-cyclohexenyl)but-3-en-2-one [FL-no: 07.200] 
•  beta-Ionyl acetate [FL-no: 09.305] 
•  Maltyl isobutyrate [FL-no: 09.525] 
Furthermore, information on one representative material, beta-damascone [FL-no: 07.083] has now 
been submitted by the European Flavour Association. This information is intended to cover also the 
re-evaluation of the following two substances. 
•  beta-Damascenone [FL-no: 07.108]  
•  trans-1-(2,6,6-Trimethyl-1-cyclohexen-1-yl)-but-2-en-1-one [FL-no: 07.224] 
                                                      
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50 
5  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting 
the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the 
Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and 
repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012,  
 p.  1-161 
6  Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96.  OJ L 180, 19.7.2000, p. 8-16 
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The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substances. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the following 15 flavouring substances: 4-(2,6,6-trimethyl-1-cyclohexenyl)but-3-en-2-
ol  [FL-no: 02.106], beta-ionone [FL-no: 07.008], methyl-beta-ionone [FL-no: 07.010], maltol [FL-no: 
07.014], beta-isomethylionone [FL-no: 07.041], beta-damascone [FL-no: 07.083], nootkatone [FL-no: 
07.089], beta-damascenone [FL-no: 07.108], 2,6,6-trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109], 
p-mentha-1,4(8)-dien-3-one [FL-no: 07.127], 4,4a,5,6-tetrahydro-7-methylnapthalen-2(3H)-one [FL-
no: 07.136], 4-(2,5,6,6-tetramethyl-1-cyclohexenyl)but-3-en-2-one [FL-no: 07.200], trans-1-(2,6,6-
trimethyl-1-cyclohexen-1-yl)-but-2-en-1-one [FL-no: 07.224], beta-ionyl acetate [FL-no: 09.305] and 
maltyl isobutyrate [FL-no: 09.525] in accordance with Commission Regulation (EC) N° 1565/2000. 
HISTORY OF THE EVALUATION OF FGE.19 SUBSTANCES 
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl 
substances via hydrolysis and/or oxidation (EFSA, 2008a). 
The  α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA, 
2008a). The Panel noted that there were limited genotoxicity data on these flavouring substances but 
that positive genotoxicity studies were identified for some substances in the group. 
The α,β-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity 
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a 
(quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of these substances 
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE 
Models and ISS-Local Models, (Gry et al., 2007)). 
The Panel noted that for most of these models internal and external validation has been performed, but 
considered that the outcome of these validations was not always extensive enough to appreciate the 
validity of the predictions of these models for these alpha, beta- unsaturated carbonyls. Therefore, the 
Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and 
decided not to take substances through the procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 
2007a; Benigni and Netzeva, 2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; 
Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as 
well as data on carcinogenicity for several substances. Based on these data the Panel decided that 15 
subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 
2008b) could not be evaluated through the Procedure due to concern with respect to genotoxicity. 
Corresponding to these subgroups, 15 Flavouring Group Evaluations (FGEs) were established: 
FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225. 
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions, 
that a further scrutiny of the data should take place before requesting additional data from the 
Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 212, 
213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218 it was concluded that a 
genotoxic potential could be ruled out and accordingly these substances will be evaluated using the 
Procedure. For all or some of the substances in the remaining FGEs, FGE.201, 203, 210, 212, 213, 
216, 217 and 220 the genotoxic potential could not be ruled out. 
To ease the data retrieval of the large number of structurally related α,β-unsaturated substances in the 
different subgroups for which additional data are requested, EFSA worked out a list of representative Flavouring Group Evaluation 213, Revision 1
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substances for each subgroup (EFSA, 2008c). Likewise an EFSA genotoxicity expert group has 
worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 2008b). 
The Flavouring Industry has been requested to submit additional genotoxicity data according to the list 
of representative substances and test strategy for each subgroup. 
The Flavouring industry has now submitted additional data and the present FGE concerns the 
evaluation of these data requested on genotoxicity. Flavouring Group Evaluation 213, Revision 1
 
EFSA Journal 2014;12(5):3661  7
ASSESSMENT 
1.  HISTORY OF THE EVALUATION OF THE SUBSTANCES BELONGING TO FGE.213 
In the EFSA Opinion “List of α,β-unsaturated aldehydes and ketones representative of FGE.19 
substances for genotoxicity testing” (EFSA, 2008c), representative flavouring substances have been 
selected for FGE.19 subgroup 2.7, corresponding to FGE.213. 
In the first scientific opinion on FGE.213 (EFSA, 2009), the Panel concluded that based on the data 
available the concern with respect to genotoxicity could be ruled out for 11 substances, [FL-no: 
07.047, 07.056, 07.057, 07.075, 07.076, 07.080, 7.117, 07.118, 07.119, 07.120 and 07.168]. Nine of 
these substances have been evaluated by the JECFA before 2000 to be of no safety concern and in 
accordance with Commission Regulation (EC) No 1565/2000 no further considerations is requested. 
The remaining two substances [FL-no: 07.047 and 07.168] will be evaluated in FGE.83Rev1 and 
FGE.11Rev2, respectively, using the Procedure. 
For maltol [FL-no: 07.014], the Panel has requested a combined in vivo micronucleus and Comet 
assay in order to clarify the genotoxic potential. The outcome would also be applicable to maltyl 
isobutyrate [FL-no: 09.525]. 
For the remaining 13 substances [FL-no: 02.106, 07.008, 07.010, 07.041, 07.083, 07.089, 07.108, 
07.109, 07.127, 07.136, 07.200, 07.224 and 09.305] additional data on genotoxicity were required for 
the representative substances, according to the Opinion of the CEF Panel on the “Genotoxicity Test 
Strategy for Substances Belonging to Subgroups of FGE.19” (EFSA, 2008b).  
 
The present FGE.213 Revision 1 (FGE.213Rev1) includes the assessment of additional genotoxicity 
data submitted by Industry (IOFI, 2012; IOFI, 2013)  in reply to a data request presented in FGE.213 
(EFSA, 2009). 
The new data submitted concerns five of the original six representative substances requested by the 
Panel (EFSA, 2008c), namely beta-ionone [FL-no: 07.008], maltol [FL-no: 07.014], beta-damascone 
[07.083], nootkatone [FL-no: 07.089] and 2,6,6-trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109], 
(Table 1). 
The flavouring Industry has informed that it does not longer support the representative flavouring 
substance, piperitenone oxide [FL-no: 16.044], for which the Panel requested additional data. 
However, since piperitenone oxide was a self-representative substance, this will not affect the 
evaluation of the remaining substances in FGE.213Rev1. 
Since the previous version of the FGE, one additional substance has been included in subgroup 2.7, tr-
1-(2,6,6-Trimethyl-1-cyclohexen-1-yl)but-2-en-1-one [FL-no: 07.224], which is structurally related to 
the other substances for which the genotoxic potential could not be ruled out. 
The new data submitted for the five representative substances are described and evaluated in Section 4 
of the present revision. Sections 2 and 3 report the same information that was present in the earlier 
version of FGE.213. 
 
FGE Adopted  by  EFSA  Link  No.  of 
Substances
FGE.213  27 November 2008  http://www.efsa.europa.eu/en/efsajournal/pub/879.htm 26 
FGE.213Rev1  10 April 2014    26 Flavouring Group Evaluation 213, Revision 1
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Table 1:   Representative substances for subgroup 2.7 of FGE.19 
FL-no  
JECFA-no   EU Register name   Structural formula   Comments  
07.008 
389 
beta-Ionone 
O In vitro assays in bacteria and 
mammalian cells submitted 
07.014 
1480 
Maltol 
O
O
OH
 
In vitro assays in bacteria and 
mammalian cells and  an in vivo 
combined Comet and micronucleus 
assay submitted 
07.083 
384 
beta-Damascone 
O
 
In vitro assays in bacteria and 
mammalian cells  and  an in vivo 
combined Comet and micronucleus 
assay submitted 
07.089 
1398 
Nootkatone 
O
 
In vitro assays in bacteria and 
mammalian cells submitted 
07.109 
1857 
2,6,6-Trimethylcyclohex-2-en 
1,4-dione 
O
O
 
In vitro assays in bacteria and 
mammalian cells submitted 
16.044 
1574 
Piperitenone oxide 
O
O
 
No longer supported by Industry and 
no data submitted 
 
2.  Presentation of the Substances in Flavouring Group Evaluation 213 
2.1.  Description 
The Flavouring Group Evaluation 213 (FGE.213) concerned 26 substances (Table 2), corresponding to 
subgroup 2.7 of FGE.19. Twenty-three of the substances are α,β-unsaturated alicyclic ketones [FL-no: 
07.008, 07.010, 07.014, 07.041, 07.047, 07.056, 07.057, 07.075, 07.076, 07.080, 07.083, 07.089, 
07.108, 07.109, 07.117, 07.118, 07.119, 07.120, 07.127, 07.136, 07.168, 07.200 and 07.224] ([FL-no 
16.044] is no longer supported by Industry and one new substance ([FL-no 07.224] has been included 
in Revision 1) and three are precursors for such ketones [FL-no: 02.106, 09.305 and 09.525]. Two of 
these substances [FL-no: 02.106 and 09.305] are precursors of the ketone beta-ionone [FL-no: 07.008] 
and one [FL-no: 09.525] is a precursor of the ketone maltol [FL-no: 07.014]. Ten of the ketones have 
the possibility for keton-enol tautomerism [FL-no: 07.056, 07.057, 07.075, 07.076, 07.080, 07.117, 
07.118, 07.119, 07.120 and 07.168]. Based on experimental evidence for other diketones it is 
anticipated that the enol is the predominant form. 
Twenty-two of the substances in the present FGE.Rev1 (including the new substance ([FL-no 07.224], 
excluding ([FL-no 16.044]) have formerly been evaluated by the JECFA (JECFA, 1999; JECFA, 
2001; JECFA, 2006a; JECFA, 2006b; JECFA, 2009a), a summary of their current evaluation status by 
the JECFA is given in Table 3. Flavouring Group Evaluation 213, Revision 1
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As the α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA, 
2008a) the available data on genotoxic or carcinogenic activity for the 26 unsaturated alicyclic ketones 
and precursor in subgroup 2.7 will be considered in this FGE. 
The Panel has also taken into consideration the outcome of the predictions from five selected (Q)SAR 
models (Benigni & Netzeva, 2007a; Gry et al., 2007; Nikolov et al., 2007) on 22 ketones [FL-no: 
07.008, 07.010, 07.014, 07.041, 07.047, 07.056, 07.057, 07.075, 07.076, 07.080, 07.083, 07.089, 
07.108, 07.109, 07.117, 07.118, 07.119, 07.120, 07.127, 07.136, 07.168 and 07.200]. The 22 ketones 
and their (Q)SAR predictions are shown in Table 4. 
3.  Toxicity
7 
3.1.  (Q)SAR Predictions 
In Table 4 the outcomes of the (Q)SAR predictions for possible genotoxic activity in five in vitro 
(Q)SAR models (ISS-Local Model-Ames test, DTU-NFI-MULTICASE-Ames test, Chromosomal 
aberration test (CHO), Chromosomal aberration test (CHL), and Mouse lymphoma test) are presented. 
Maltol [FL-no: 07.014], ethyl maltol [FL-no: 07.047] and nootkatone [FL-no: 07.089] were predicted 
positive with the MultiCASE model on chromosomal aberrations in CHL cells. All other predictions 
were negative or the substances were out of domain. 
3.2.  Genotoxicity Studies 
In subgroup 2.7 there are studies available for four substances. For maltol [FL-no: 07.014] eight in 
vitro and three in vivo studies have been evaluated. For ethyl maltol [FL-no:07.047] two in vitro and 
one in vivo study were evaluated. Numbers of evaluated in vitro studies concerning beta-ionone [FL-
no: 07.008] and 3-methylcyclopentan-1,2-dione [FL-no: 07.056] were two and one, respectively. 
Study validation and results are presented in Tables 5 and 6. 
In studies which were considered valid, the following results were obtained: 
Maltol induced gene mutations in bacteria (Bjeldanes and Chew, 1979) and sister chromatid 
exchanges in human lymphocytes (Jansson et al., 1986). In vivo, maltol induced micronuclei in mouse 
bone marrow after intraperitoneal application (Hayashi et al., 1988). Negative results were obtained in 
a sex-linked recessive lethal mutation assay in Drosophila (Mason et al., 1992). However, the 
micronucleus assay is considered more relevant than the Drosophila assay. 
Ethyl maltol induced gene mutations in bacteria (Bjeldanes and Chew, 1979). 
A negative result was obtained with beta-ionone in a gene mutation assay in bacteria (Mortelmans et 
al., 1986). 
The validity of other studies was limited or could not be evaluated. 
3.3.  Carcinogenicity Studies 
In a combined study of developmental toxicity and carcinogenicity, three successive generations of 
male and female Charles River CD-COBS rats received 3-ethyl-2-hydroxy-2-cyclopenten-1-one (due 
to keto-enol tautomerism this substance can exist as two isomers; the keto-isomer is 3-
ethylcyclopentan-1,2-dione [FL-no: 07.057], a synonym for the keto-isomer is ethylcyclopentenolone) 
in the basal diet at doses of 0 (untreated control), 0 (propylene glycol control), 30, 80 or 200 mg/kg 
body weight (bw) per day. The F1 generation was initially exposed in utero, subsequently via the 
                                                      
7  The data presented in Section 3 is cited from the first version of the present FGE.213. These data are the basis for the 
conclusions in FGE.213 requesting additional genotoxicity data. Flavouring Group Evaluation 213, Revision 1
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dams' milk until weaning, and then treated for two years and bred twice (at days 99 and 155). In the F1 
generation, there were 100 animals of each sex in the untreated control group and 50 of each sex in the 
propylene glycol control and 3-ethyl-2-hydroxy-2-cyclopenten-1-one-treated groups. Survival, clinical 
symptoms, food consumption, reproductive performance, and haematological and clinical chemical 
parameters were not adversely affected. Gross pathological and histopathological examination 
revealed no significant treatment-related effects. The incidence of benign or malignant tumours in 
treated animals was similar to that in controls. The No Observed Effect Level (NOEL) was 200 mg/kg 
bw per day (King et al., 1979).  
The Panel concluded that 3-ethyl-2-hydroxy-2-cyclopenten-1-one (3-ethylcyclopentan-1,2-dione [FL-
no: 07.057]) was not carcinogenic in rats under the study conditions. 
Groups of 25 male and female rats were fed for two years on diets containing ethyl maltol [FL-no: 
07.047] calculated to deliver 0, 50, 100 and 200 mg ethyl maltol/kg bw/day. No abnormalities were 
seen as regards survival, clinical appearance, growth rate or food consumption, clinical chemistry, 
haematology and urinalysis. No histopathological changes and no increases in neoplasms were seen 
after the treatment with ethyl maltol (Gralla et al., 1969). 
Study validation and results are presented in Table 7. 
The Panel noted that this study was performed before OECD test guidelines 451/453 (1981) have been 
established and it does not meet the criteria of these OECD test guidelines with respect to the number 
of animals. However, the Panel concluded that ethyl maltol was not carcinogenic in rats in this study. 
3.4.  Conclusion on Genotoxicity and Carcinogenicity 
For the substances of this group, the applicability of the (Q)SAR models is very limited since many 
substances were out of domain in the ISS model and the MultiCASE models. 
Two substances [FL-no: 02.106 and 09.305] are precursors of beta-ionone [FL-no: 07.008] and 
therefore, the conclusions for these two precursors could be based on the conclusions drawn for the 
corresponding ketone [FL-no: 07.008]. Maltyl isobutyrate [FL-no: 09.525] is a precursor of maltol 
[FL-no: 07.014], and accordingly, the conclusion for maltyl isobutyrate could be based on the 
conclusion drawn for maltol. 
Maltol and ethyl maltol were considered separately because in contrast to the other substances in this 
subgroup they contain a ring-oxygen atom.  
There is a carcinogenicity study on ethyl maltol [FL-no: 07.047] in rats. Although the number of 
animals per group were lower than suggested in OECD guidelines they were in accordance with the 
standards at the time the study was performed and the Panel concluded that the result could overrule 
the mutagenicity observed with ethyl maltol in bacteria but not the mutagenicity observed with maltol 
[FL-no: 07.014] in vitro and in vivo. Since the micronuclei induced by maltol in mice were analysed 
after intraperitoneal application, a micronucleus assay after oral application is required in addition to 
an in vivo Comet assay in order to clarify the genotoxic potential of maltol. A combination of the 
micronucleus assay and the Comet assay in a single study would also be acceptable. The result of 
these assays would also be applicable to maltyl isobutyrate [FL-no: 09.525] which is a precursor of 
maltol. 
No carcinogenicity was observed with 3-ethyl-2-hydroxy-2-cyclopenten-1-one [FL-no: 07.057] in rats. 
This substance was considered representative for nine substances [FL-no: 07.117, 07.118, 07.119, 
07.120, 07.056, 07.168, 07.075, 07.076 and 07.080]. Therefore, the Panel concluded that the structural 
alert for genotoxicity is overruled for 3-ethyl-2-hydroxy-2-cyclopenten-1-one [FL-no: 07.057] as well 
as for the nine structurally related substances.  Flavouring Group Evaluation 213, Revision 1
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For the 13 remaining substances (including two precursors of a ketone) [FL-no: 02.106, 07.008, 
07.010, 07.041, 07.083, 07.089, 07.108, 07.109, 07.127, 07.136, 07.200, 09.305 and 16.044] a 
genotoxic potential could not be ruled out since only one valid negative bacterial genotoxicity study 
on [FL-no: 07.008] is available for these substances. 
3.5.  Conclusions 
The Panel concluded that ethyl maltol [FL-no: 07.047], 3-ethylcyclopentan-1,2-dione [FL-no: 07.057] 
and the nine structurally related substances [FL-no: 07.117, 07.118, 07.119, 07.120, 07.056, 07.168, 
07.075, 07.076 and 07.080] can be evaluated through the Procedure. 
For maltol [FL-no: 07.014], a micronucleus assay after oral application is required in addition to an in 
vivo Comet assay in order to clarify the genotoxic potential. A combination of the micronucleus assay 
and the Comet assay in a single study would also be acceptable. The outcome would also be applicable 
to maltyl isobutyrate [FL-no: 09.525]. 
The remaining 13 substances (including two precursors of a ketone) [FL-no: 02.106, 07.008, 07.010, 
07.041, 07.083, 07.089, 07.108, 07.109, 07.127, 07.136, 07.200, 09.305 and 16.044] cannot presently 
be evaluated through the Procedure. Additional data on genotoxicity are requested for representative 
substances of this subgroup according to the opinion of the Panel on the Genotoxicity Test Strategy for 
Substances Belonging to Subgroups of FGE.19 (EFSA, 2008b). 
4.  Industry Response to Data Requested in FGE.213 
4.1.  Presentation of the Additional Data 
Based on Panel requirements published in FGE.213 (EFSA, 2009), additional data have been provided 
by the Industry for the representative substances: beta-ionone [FL-no: 07.008], maltol [FL-no: 
07.014], beta-damascone [FL-no: 07.083], nootkatone [FL-no: 07.089],  and 2,6,6-trimethylcyclohex-
2-en-1,4-dione [FL-no: 07.109] 
The present FGE.213, Revision 1 (FGE.213Rev1), includes the assessment of these additional 
genotoxicity data. The study types provided are shown below: 
Substance / study type Bacterial  Mutation  In Vitro 
Micronucleus 
In Vivo Micronucleus 
combined with Comet  
beta-Ionone 
[FL-no: 07.008]  (Ballantyne, 2011)   (Stone, 2011a)    
Maltol 
[FL-no: 07.014]   (Ballantyne, 2012)  (Whitwell, 2012)   (Beevers, 2013a) 
beta-Damascone 
[FL-no: 07.083]  (Bowen, 2011b)  (Stone, 2012)  (Beevers, 2013b; 
Beevers, 2013c) 
Nootkatone 
[FL-no: 07.089]  (Marzin, 1998)  (Stone, 2011b)   
2,6,6-Trimethylcyclohex-2-en-1,4-dione 
[FL-no: 07.109]  (Bowen, 2011a)  (Lloyd, 2011)   
 Flavouring Group Evaluation 213, Revision 1
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4.2.  In vitro data 
4.2.1.  Bacterial Reverse Mutation Assay 
beta-Ionone [FL-no: 07.008] 
beta-Ionone [FL-no: 07.008] was tested in Salmonella typhimurium strains TA98, TA100, TA1535, 
TA1537 and TA102 in the absence and presence of S9-mix (Ballantyne, 2011). In the first experiment, 
the concentrations were 0.32, 1.6, 8, 40, 200, 1000 and 5000 µg/plate of beta-ionone and the plate 
incorporation methodology was used. Toxicity ranging from slight thinning of the background lawn to 
complete killing of the tester strains was observed at 1000 and/or 5000 µg/plate for all tester strains in 
the absence and presence of S9-mix. In the second experiment, the concentrations were 10.24, 25.6, 
64, 160, 400 and 1000 µg/plate and the treatments in the presence of S9-mix used the pre-incubation 
method. Toxicity ranging from thinning of the background lawn and/or reduction in revertant numbers 
to complete killing of the tester bacteria occurred in all strains at 1000 µg/plate in the absence and 
presence of S9-mix and was also seen down to 160 and/or 400 µg/plate for some individual strains. 
The study design complied with current recommendations and an acceptable top concentration was 
achieved. There was clearly no evidence of any mutagenic effect induced by beta-ionone in any of the 
strains, either in the absence or presence of S9-mix. 
Maltol [FL-no: 07.014] 
Maltol [FL-no: 07.014] was tested in S. typhimurium strains TA98, TA100, TA1535, TA1537 and 
TA102 in the absence and presence of S9-mix (Ballantyne, 2012). In the first experiment, the 
concentrations were 0.32, 1.6, 8, 40, 200, 1000 and 5000 µg/plate of maltol and the plate incorporation 
methodology was used. Toxicity in the form of reduction of the number of revertants in the tester 
strain TA102 was observed at 200 µg/plate and above in the presence of S9-mix and 1000 and 5000 
µg/plate in the absence of S9-mix. In the second experiment, the concentrations were 51.2, 128, 320, 
800, 2000 and 5000 µg/plate and the treatments in the presence of S9-mix used the pre-incubation 
method in all strains. In tester strain TA102 an additional lower concentration of 20.48 µg/plate was 
incorporated into the testing protocol in both the absence and presence of S9 to more carefully assess 
the toxicity observed in Experiment 1. Toxicity in the form of thinning of the background lawn and/or 
reduction in numbers of revertants occurred at the 5000 µg/plate concentration in strain TA102 in the 
absence and presence of S9-mix and in strain TA100 only in the presence of S9-mix. The study design 
complied with current recommendations and an acceptable top concentration was achieved. There was 
no evidence of any mutagenic effect induced by maltol in any of the strains, either in the absence or 
presence of S9-mix. 
beta-Damascone [FL-no: 07.083] 
An Ames assay was conducted in Salmonella typhimurium strains TA98, TA100, TA1535, TA1537, 
and TA102 to assess the mutagenicity of beta-damascone (purity: 95 %), both in the absence and in 
the presence of metabolic activation by S9-mix, in three separate experiments (Bowen, 2011b). The 
assay was performed according to OECD Guideline 471 (1997a) and according to GLP principles.  
An initial experiment was carried out both in the absence and presence of S9-mix activation in all five 
strains, using final concentrations of beta-damascone between 0.32 - 5000 μg/plate (0.32, 1.6, 8, 40, 
200, 1000, 5000 μg/plate), plus negative (solvent) and positive controls. Evidence of toxicity was 
observed through thinning of the background lawn to complete killing at 1000 μg/plate and above for 
strains TA1535, TA1537 and TA102 and/or 5000 μg/plate for strains TA98 and TA100 in the absence 
and presence of S9-mix. In the second experiment the highest concentration was retained for strains 
TA98 and TA100 in the absence and presence of S9-mix. In all other tester strains, the highest dose 
was reduced to 2500 μg/plate based on toxicity observations. In addition, more narrow concentration 
intervals were used, starting at either 78.13 μg/plate or 156.3 μg/plate (78.13, 156.3, 312.5, 625, 1250, 
2500 μg/plate). The standard plate incorporation assay was used in the first experiment but a pre-Flavouring Group Evaluation 213, Revision 1
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incubation step with S9-mix activation treatment was added in the second experiment to increase the 
chance of detecting a positive response. Evidence of toxicity was observed in TA98 at 625 μg/plate in 
the presence of S9-mix in addition to strains TA1535, 1537 and TA 102 in the absence and presence 
of S9-mix, at 1250 μg/plate and above in strain TA98 in the absence of S9-mix and TA100 in the 
presence of S9-mix and TA100 in the absence of S9-mix at 2500 μg/plate and above. 
The third experiment was conducted using strain TA98 in the presence of S9-mix activation using the 
pre-incubation method. The maximum test concentration was reduced to 1250 μg/plate based on 
toxicity observed in the previous experiments. In addition, more narrow concentration intervals were 
used, covering 19.53 to 1250 μg beta-damascone/plate (19.53, 39.06, 78.13, 156.3, 312.5, 625 and 
1250 μg/plate). Evidence of toxicity was observed at the highest four concentrations in strain TA98 in 
the presence of S9-mix. In all three experiments, no statistically significant increases in revertant 
numbers were observed at any concentration, in any of the strains, either in the presence or absence of 
S9-mix activation.  
The Panel agreed with the conclusion of the study authors that beta-damascone did not induce 
mutations in five strains of Salmonella typhimurium, when tested under the conditions of this study. 
Nootkatone [FL-no: 07.089] 
Nootkatone [FL-no: 07.089] was tested in S. typhimurium strains TA98, TA100, TA1535, TA1537 
and TA102 in the absence or presence of S9-mix (Marzin, 1998). A preliminary toxicity test to 
identify appropriate concentrations for the mutagenicity assays was performed in the absence and 
presence of S9-mix, and cytotoxicity was observed at 50 μg/plate in the absence of S9-mix and at 150 
μg/plate in the presence of S9-mix. In the first mutagenicity experiment using plate incorporation 
methodology the concentrations tested were 0.5, 1.5, 5, 15 and 50 μg/plate in the absence of S9-mix 
metabolic activation and 1.5, 5, 15, 50 and 150 μg/plate in the presence of S9-mix. In the second 
experiment the plate incorporation method was used in absence of S9 and the concentrations were 0.5, 
1.5, 5, 15 and 50 μg/plate. While the pre-incubation method was used in the presence of S9-mix and 
the concentrations were and 0.5, 1.5, 5, 15, 50 and 150 μg/plate. Thus, the study design complied with 
current recommendations and an acceptable top concentration was achieved. There was no evidence of 
any mutagenic effect induced by nootkatone in any of the strains, either in the absence or presence of 
S9-mix. 
2,6,6-Trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109] 
2,6,6-Trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109] was tested in S. typhimurium strains TA98, 
TA100, TA1535, TA1537 and TA102 in the absence and presence of S9-mix (Bowen, 2011a). In the 
first experiment, the concentrations tested were 0.32, 1.6, 8, 40, 200, 1000 and 5000 μg/plate and plate 
incorporation methodology was used. In the second experiment, the concentrations were 156.3, 312.5, 
625, 1250, 2500 and 5000 µg/plate of 2,6,6-trimethylcyclohex-2-en-1,4-dione and treatments in the 
presence of S9-mix used the pre-incubation method. The test chemical elicited evidence of 
cytotoxicity in the form of background lawn thinning or marked reduction of the number of revertants 
in experiment 1 at 1000 and/or 5000 µg/plate in strains TA102 and TA1535 in the presence of S9-mix 
and in experiment 2 at 2500 and/or 5000 µg/plate in strain TA102 in the absence and presence of S9-
mix. Thus, the study design complied with current recommendations and an acceptable top 
concentration was achieved. There was no evidence of any mutagenic effect induced by 2,6,6-
trimethylcyclohex-2-en-1,4-dione in any of the strains, either in the absence or presence of S9-mix. 
Summary of the Bacterial Reverse Mutation Assay for all the substances are reported in Table 8.  Flavouring Group Evaluation 213, Revision 1
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4.2.2.  Micronucleus Assays 
beta-Ionone [FL-no: 07.008] 
beta-Ionone [FL-no: 07.008] was evaluated in an in vitro micronucleus assay in human peripheral 
blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in the presence and 
absence of rat liver S9-mix fraction as an in vitro metabolising system. Cells were stimulated for 48 
hours with phytohaemagglutinin to produce exponentially growing cells and then treated for 3 hours 
(followed by 21 hours recovery) with 0, 30, 50 or 60 µg/ml of beta-ionone in the absence of S9-mix 
and 0, 80, 100 or 120 µg/ml in the presence of S9-mix. The levels of cytotoxicity (reduction in 
replication index) at the top concentrations were 52 % and 59 %, respectively. In a parallel assay, cells 
were treated for 24 hours with 0, 5, 15 and 17.50 µg/ml of beta-ionone in the absence of S9-mix with 
no recovery period. The top concentration induced 58 % cytotoxicity. There were 2 replicate cultures 
per treatment and 1000 binucleate cells per replicate were scored for micronuclei. Thus, the study 
design complies with current recommendations (OECD Guideline 487), and acceptable levels of 
cytotoxicity were achieved at the top concentrations used in all parts of the study. Treatment of cells 
with beta-ionone for 3 hours with a 21 hours recovery period showed an increase in the frequency of 
MNBN cells in one single replicate at the concentration of 30 and 120 µg/ml (0.9 % and 1.5 %, 
respectively) in the absence and presence of S9-mix, respectively. At 30 µg/ml, the lowest 
concentration tested in the absence of S9-mix, the increase in the frequency of MNBN cells was 
slightly above the 95 % confidence interval of the historical control range (0.2 - 0.8 %). Also in the 
presence of S9-mix, one replicate of the lowest concentration tested (80 µg/ml) had an increase in the 
frequency of MNBN cells at the upper limit of the 95 % confidence interval of the historical control 
range (0.10 - 1.10 %) but did not reach statistical significance. To ensure that these single occurrences 
are random an additional 1000 binucleate cells were scored from the concurrent controls, 80 and 120 
µg/ml cultures. The scoring of further cells resulted in overall mean frequencies of MNBN cells that 
were not significantly different from concurrent controls and fell below the upper 95 % confidence 
interval of the normal control range (recalculated due to change of stain), and therefore showed that 
the earlier increases were due to chance. It was concluded that beta-ionone [FL-no: 07.008] did not 
induce micronuclei up to toxic concentrations when assayed in cultured human peripheral 
lymphocytes for 3 + 21 hours in the absence and presence of S9-mix or when incubated for 24 + 0 
hours in the absence of S9-mix (Stone, 2011a). 
Maltol [FL-no: 07.014] 
Maltol [FL-no: 07.014] was evaluated in an in vitro micronucleus assay in human peripheral blood 
lymphocytes for its ability to induce chromosomal damage or aneuploidy in the presence and absence 
of rat liver S9-mix fraction as an in vitro metabolising system (Whitwell, 2012). Cells were stimulated 
for 48 hours with phytohaemagglutinin to produce exponentially growing cells and then treated for 3 
hours (followed by 21 hours recovery) with 0, 400, 800 or 1262 µg/ml of maltol, the latter being 
equivalent to 10 mM, in the absence and presence of S9-mix. The levels of cytotoxicity (reduction in 
replication index) at the top concentrations were 24 % and 19 %, respectively. In a parallel assay, cells 
were treated for 24 hours with 0, 125, 200 and 300 µg/ml of maltol in the absence of S9-mix with no 
recovery period. The top concentration induced 57 % cytotoxicity. There were 2 replicate cultures per 
treatment, and 1000 binucleate cells per replicate (i.e. 2000 cells per concentration) were scored for 
micronuclei. Thus, the study design complies with current recommendations (OECD Guideline 487), 
and acceptable top concentrations, either 10 mM or 50 - 60 % toxicity, were achieved in all parts of 
the study. A statistically significant increase in the occurrence of MNBN cells was observed following 
3 + 21 hours treatment in the presence of S9-mix at the two highest concentrations scored. Statistically 
significant and concentration-dependent increases in MNBN were seen in the 3 + 21 hours treatment 
groups in the absence of S9-mix, but it was noted that the increases at the two highest concentrations 
scored only exceeded historical control ranges in one of the two replicate cultures. No increases were 
observed in the frequency of MNBN in cells that received continuous (24 + 0 hours) treatment, but 
due to the cytotoxicity of maltol, lower concentrations were analysed. To further investigate these 
observations, fluorescence in situ hybridisation (FISH) analysis using human pan-centromeric probes Flavouring Group Evaluation 213, Revision 1
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was conducted to assess whether the mechanism of action could be attributed to chromosome loss 
(aneuploidy) or chromosome breakage (clastogenicity). Slides were prepared from the two highest 
concentrations (800 and 1262 µg/ml) in the absence and presence of S9-mix. The FISH analysis 
revealed that following maltol treatment the majority (69 - 76 %) of micronuclei did not contain a 
centromere. The Panel concluded that maltol induced micronuclei in vitro in cultured human 
peripheral blood lymphocytes in the presence of rat liver metabolic activation (S9-mix) via a 
clastogenic mechanism of action (Whitwell, 2012). However, the Panel considered that the results 
observed in the absence of S9 were equivocal due to the fact that the increases observed (which were 
statistically significantly different from concurrent solvent control) were not reproduced in replicate 
cultures. 
beta-Damascone [FL-no:07.083] 
beta-Damascone (purity: 95 %) was evaluated in an in vitro micronucleus assay in human peripheral 
blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in the presence and 
absence of rat S9 fraction as an in vitro metabolising system (Stone, 2012). Cells were stimulated for 
48 hours with phytohaemaglutinin to produce exponentially growing cells and then treated for 3 hours 
(followed by 21 hours recovery) with a large range of concentrations from 2 to 30 µg/ml. For the 
treatment of 3 hours with a 21 hour recovery period, the concentrations of beta-damascone at 8, 16 and 
22 μg/ml or at 12, 16, 18 μg/ml were retained for MN numeration, in the absence or in the presence of 
S9-mix respectively. The levels of cytotoxicity (reduction in replication index) at the top 
concentrations were 59 % and 51 %, respectively. Thus, the study design complies with OECD 
Guideline 487 and follows GLP principles. 
In a parallel assay, cells were treated for 24 hours (with no recovery period) in the absence of S9-mix 
with a large range of concentrations from 1 to 15 µg/ml and the concentrations of  6, 8 and 9 μg/ml of 
beta-damascone were retained for MN numeration. The top concentration induced 57 % cytotoxicity. 
There were 2 replicate cultures per treatment and 1000 binucleate cells per replicate were scored for 
micronuclei. The study design complies with current recommendations (OECD Guideline 487, 2010), 
and acceptable levels of cytotoxicity were achieved at the top concentrations used in all parts of the 
study.  
Treatment of cells with beta-damascone for 3  +  21 hours in the presence of S9-mix showed a 
statistically significant concentration-dependent increase in the induction of MNBN cells with 0.55, 
2.10 and 2.70 % MNBN cells vs. 0.35 % in the concurrent control and 0.1 to 1.1 % for the historical 
controls.  
Treatment of cells with beta-damascone for 3 + 21 and 24 + 0 hours in the absence of S-9 resulted in 
sporadic increases in MNBN frequency. These increases were only observed in single replicates and 
were not concentration related. Therefore, the effect of beta-damascone was further investigated 
through the scoring of additional cells (2 more replicates of 1000 cells each) from the affected 
concentrations and concurrent controls. 
Treatment of cells, in the absence of S9-mix, for 3  +  21 hours induced a statistically significant 
increase in the frequency of MNBN cells at 8 and 22 µg/ml (0.80 % and 0.93 %, respectively) 
compared to concurrent control (0.38 %), but not at the mid dose of 16 µg/ml (0.53 % MNBN cells). 
The frequency of MNBN cells exceeded the historical controls (0.2 - 0.8 %) in 3 out of 4 replicates at 
the highest concentration tested (22 µg/ml). Treatment of cells for 24 hours with no recovery period in 
the absence of S9-mix showed statistically significant increase in the frequency of MNBN cells at the 
mid dose of 8 µg/ml (0.95 % MNBN cells) when compared to concurrent control (0.40 %) with no 
correlation to concentration. The frequency of MNBN cells exceeded the historical controls (0 - 1.1 
%) only in 1 replicate at 8 µg/ml.  
The authors considered that this result reaffirmed the sporadic nature of the induction of MNBN cells 
in the absence of S9-mix. It was concluded that the treatment with beta-damascone for 3 + 21 hours or Flavouring Group Evaluation 213, Revision 1
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24 + 0 hours (in the absence of S9-mix) induced sporadic increases in MNBN cells when compared to 
concurrent controls and not concentration related, therefore the results were considered equivocal. In 
the same test system, beta-damascone did induce micronuclei in cultured human peripheral blood 
lymphocytes following 3+21 hours treatment in the presence of S9-mix (Stone, 2012). The Panel 
noted that after the new reading of slides the increase of MNBN cells frequency was still statistically 
significant even at weak cytotoxic levels. 
Therefore, the Panel concluded that beta-damascone is genotoxic in the in vitro micronucleus assay on 
human lymphocytes with metabolic activation and equivocal without metabolic activation. 
Nootkatone [FL-no: 07.089] 
Nootkatone [FL-no: 07.089] was evaluated in an in vitro micronucleus assay in human peripheral 
blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in the presence and 
absence of rat S9-mix fraction as an in vitro metabolising system (Stone, 2011b). Cells were 
stimulated for 48 hours with phytohaemagglutinin to produce exponentially growing cells and then 
treated for 3 hours (followed by 21 hours recovery) with 0, 50, 70 or 80 µg/ml of nootkatone in the 
absence of S9-mix and 0, 160, 180 and 185 µg/ml in the presence of S9-mix, respectively. The levels 
of cytotoxicity (reduction in replication index) at the top concentrations were 60 and 58 %, 
respectively. In a parallel assay, cells were treated for 24 hours with 0, 10, 15, 22 and 24 µg/ml of 
nootkatone in the absence of S9-mix with no recovery period. The top concentration induced 62 % 
cytotoxicity. There were 2 replicate cultures per treatment and 1000 binucleate cells per replicate (i.e. 
2000 cells per dose) were scored for micronuclei. The study design complies with current 
recommendations (OECD Guideline 487) and acceptable levels of cytotoxicity were achieved at the 
top concentrations used in all parts of the study. No evidence of chromosomal damage or aneuploidy 
was observed as frequencies of MNBN cells were not significantly different from concurrent controls 
and fell within historical control ranges for all treatments with nootkatone in the presence or absence 
of S9-mix metabolic activation (Stone, 2011b). 
2,6,6-Trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109] 
2,6,6-Trimethylcyclohex-2-en-1,4-dione was evaluated in an in vitro micronucleus assay in human 
peripheral blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in the 
presence and absence of rat S9-mix fraction as an in vitro metabolising system (Lloyd, 2011). Cells 
were stimulated for 48 hours with phytohaemagglutinin to produce exponentially growing cells and 
then treated for 3 hours (followed by 21 hours recovery) with 0, 500, 1000 or 1522 µg/ml of 2,6,6-
trimethylcyclohex-2-ene-1,4-dione in the absence of S9-mix and 0, 1000, 1250 and 1522 µg/ml in the 
presence of S9-mix, respectively, the top concentration being equivalent to 10 mM. The levels of 
cytotoxicity (reduction in replication index) at the top concentrations were 3 % and 9 %, respectively. 
In a parallel assay, cells were treated for 24 hours with 0, 300, 420 and 550 µg/ml of 2,6,6-
trimethylcyclohex-2-ene-1,4-dione in the absence of S9-mix with no recovery period. The top 
concentration induced 57 % cytotoxicity. There were 2 replicate cultures per treatment and 1000 
binucleate cells per replicate (i.e. 2000 cells per concentration) were scored for micronuclei. The study 
design complies with current recommendations (OECD Guideline 487), and acceptable top 
concentrations, either 10 mM or 50  -  60 % toxicity, were achieved in all parts of the study. No 
evidence of chromosomal damage or aneuploidy was observed as frequencies of MNBN cells were not 
significantly different from concurrent controls and fell within historical ranges for all 2,6,6-
trimethylcyclohex-2-ene-1,4-dione  treatments in the presence or absence of S9-mix metabolic 
activation (Lloyd, 2011). 
The results of  in vitro micronucleus studies are summarised in Table 8. Flavouring Group Evaluation 213, Revision 1
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4.3.  Genotoxicity in vivo data 
4.3.1.  In vivo Combination Assay (Comet + Micronucleus) 
Since no positive results were seen in either the bacterial mutation assay or in vitro micronucleus tests 
with beta-ionone [FL-no: 07.008], nootkatone [FL-no: 07.089] or 2,6,6-trimethylcyclohex-2-en-1,4-
dione [FL-no: 07.109], no in vivo follow-up testing was required. To address the effects seen in the in 
vitro  micronucleus assay with maltol [FL-no: 07.014] and beta-damascone [FL-no: 07.083] a 
combination assay comprising of a liver Comet assay and an in vivo micronucleus assay in rat, after 
oral application, was performed to further assess the genotoxic potential for both substances. The 
results are summarised in Table 9. 
Maltol [FL-no: 07.014] 
Maltol was evaluated in an in vivo micronucleus assay and liver Comet assay in male Han Wistar 
(HsdHan:WIST) rats, 6 rats per dose group (Beevers, 2013a). The rats were administered 3 doses of 
70, 350 and 700 mg/kg bw of maltol by oral gavage at time 0, 24 and 45 hours. Rats were killed and 
sampled at 48 hours post the initial dose. The maximum tolerable dose was estimated to be 700 mg/kg 
bw/day based on a range finding study at doses of maltol of 360, 500, 700, 1000, 1500 and 2000 
mg/kg bw/day. Clinical observations (piloerection, ataxia, bradypnoea) and mortalities were observed 
from dose-level of 1000 mg/kg bw/day. For the micronucleus assay 2000 polychromatic erythrocytes 
(PCE) per rat were scored. The negative control had a normal, low frequency (0.11 %) of 
micronucleated polychromatic erythrocytes (MNPCE) and a ratio of 53.7 % PCE. The positive control 
group resulted in a significant increase in MNPCEs (1.58 %) accompanied by some bone marrow 
toxicity (29.57 % PCE). Although an individual rat in the 700 mg/kg maltol dose group showed a 
frequency of 9 MNPCE, which resulted in significant heterogeneity in this dose group, this was 
considered an outlying data point due to the other 5 rats in the group exhibiting normal control level 
MNPCE frequencies (Beevers, 2013a). Overall, the results showed that there were no statistically 
significant increases in micronucleus frequency for any dose group after oral treatment with maltol 
when compared to the vehicle control group. However, in the main experiment, at the dose levels 
selected, no clinical signs and bone marrow toxicity were observed in any animal in the maltol-treated 
groups which may reflect the possibility that the bone marrow and liver were not exposed.  
In order to clarify this issue, the Panel requested plasma analysis for proof of exposure. Plasma for 
assay has been obtained from two satellite groups of male animals (3 + 3 animals) dosed with maltol 
by oral gavage at 700 mg/kg bw/day, during conduction of the main study (Beevers, 2013a). Plasma 
obtained from 0.5 ml blood drawn from the jugular vein from each animal was frozen in the event that 
analysis for proof of exposure and toxicokinetics were required. All doses of maltol were given as 
three administrations, at 0, 24 and 45 hours. A number of three samples of plasma were obtained from 
one group of animals at 0.5, 2 and 8 hours and three samples from the other group at 1, 4 and 24 hours 
from the last administration. Analysis of maltol in plasma was performed using a gas chromatography 
with mass selective detection (GC-MSD) method. From an analytical point of view, the Panel 
considered the employed approach that was based on the use of ethylmaltol as internal standard as 
sufficient. Results showed a marked inconsistence between sampling times and animals. In samples 
collected at 0.5, 2 and 8 hours from last administration maltol was found in 2 out of 3 satellite animals 
at plasma concentrations of 265 - 283 µg/ml after 0.5 and 2 hours but not longer detectable after 8 
hours. In the plasma of the third animal maltol was not detectable at any time. On the other hand, in 
samples from another animal group (n = 3) collected at 1, 4 and 24 hours from last administration, 
maltol was found at levels of 75 - 106 µg/l after 1 hour in all 3 animals and not longer detectable after 
4 and 24 hours (Mallinson and Hough, 2014). The authors concluded that results obtained provide 
evidence that maltol is present in plasma shortly after dosing. However, the Panel did not agree with 
this conclusion and it considered the results of the bioanalytical study as inconclusive. 
In the combined Comet assay, liver of rats were removed at 48 hours after the first dose (i.e. 3 hours 
after the final dose), cut into small pieces and forced through a bolting cloth. Single cell suspensions Flavouring Group Evaluation 213, Revision 1
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were embedded in low melting point agarose on slides and lysed. The DNA was unwound and 
subjected to electrophoresis at pH > 13 and then neutralised according to standard techniques. For 
each animal, 100 cells (50 cells/slide from 2 slides) were scored for comets (tail intensity and tail 
moment) using commercial image analysis equipment.  
The Comet assay did not reveal cytotoxicity, necrosis or apoptosis in the hepatocytes as assessed by 
cloud and halo analysis and the groups treated with maltol showed mean % tail intensities and tail 
moments that were similar to vehicle controls and fell within historical control ranges. The positive 
control group treated with ethyl methanesulphonate (EMS) showed significant increases in both 
parameters (Beevers, 2013a).  
Considering that maltol has been shown to induce micronuclei in mouse bone marrow after 
intraperitoneal injection, the Panel concludes that negative findings observed in the combined bone 
marrow micronucleus test and Comet assay in the liver of treated rats could not rule out the concern 
for genotoxicity for maltol since the data provided to prove systemic availability were considered 
inconclusive due to the inconsistency of the data.  
beta-Damascone [FL-no:07.083] 
A combined in vivo micronucleus assay/liver Comet assay was performed after oral application of 
beta-damascone (purity: 95.6 %) to further assess the genotoxic potential of beta-damascone and 
damascones more generally. The results are summarised in Table 9. beta-Damascone was evaluated in 
an in vivo micronucleus assay and liver and duodenum Comet assay in groups of 6 male Han Wistar 
(HsdHan:WIST) rats per dose group (Beevers, 2013c). Based on a range finding study, 500 mg/kg/day 
was considered an appropriate estimate of the MTD because the doses of 750 mg/kg/day and above 
induced moderate to severe clinical signs of toxicity, which included piloerection, decreased activity, 
hunched posture and abnormal breathing. The rats were administered 3 doses of 125, 250 and 500 
mg/kg bw of beta-damascone by oral gavage at time 0, 24 and 45 hours. The rats were sacrificed and 
sampled at 48 hours post the initial dose. 
Animals administered beta-damascone showed clear findings during pathological analysis. 
Hepatocytes vacuolation was present in animals given 500 mg/kg/day, and was characterised by 
scattered, occasionally shrunken hepatocytes with perinuclear cytoplasmic eosinophilia and peripheral 
cytoplasmic vacuolation. Single cell necrosis was present in a single animal given 500 mg/kg/day. 
Single cell necrosis was characterised by death of individual hepatocytes throughout the liver, with 
limited inflammatory cell involvement. There was a dose-related reduction in the level of glycogen 
vacuolation in animals given 250 or 500 mg/kg/day. Glycogen vacuolation was characterised by 
generally perinuclear, clear, variably sized, indistinctly defined, vacuoles. Finally, increased mitosis 
was present in animals from all groups given beta-damascone. The greatest severity was present in 
animals given 250 mg/kg/day, and the lowest incidence was present in animals given 500 mg/kg/day. 
Increased mitosis was characterised by an increase, above the normal low background incidence, of 
mitotic figures within the liver parenchyma. Collectively, these findings indicate that the test animals 
were systemically exposed to beta-damascone. 
The negative control had a 0.11 % average rate of micronucleated polychromatic erythrocytes 
(MNPCE) and a ratio of 50.2 % polychromatic erythrocytes (PCE); 125 mg/kg beta-damascone 
treatment group had a MNPCE rate of 0.09 % and PCE ratio of 49.17 %; 250 mg/kg treatment group 
had 0.09 % MNPCE rate and 52.30 % PCE ratio; 500 mg/kg treatment group showed 0.06 % 
MNPCEs and 37.63 % PCE ratio. The positive control group resulted in 1.54 % MNPCEs and a 43.17 
% PCE ratio (Beevers, 2013c). The group mean frequencies observed were similar to concurrent 
vehicle controls for all dose groups and also were within the historical control values (mean: 0.12 %). 
There was a reduction in PCE ratio at the highest dose level indicating bone marrow toxicity, which 
demonstrates target organ exposure. These results showed that there was no statistically significant 
increase in micronucleus induced with beta-damascone under these test conditions when compared to 
negative control group. In addition, there were no statistically significant differences among Flavouring Group Evaluation 213, Revision 1
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erythrocyte parameters examined in this study. It was concluded that beta-damascone did not induce 
micronucleated erythrocytes in rat bone-marrow cells following administration by oral gavage. 
The Comet assay in the liver tissue did not reveal cytotoxicity, necrosis or apoptosis in the hepatocytes 
as assessed by cloud and halo analysis. Hepatocytes of rats dosed with beta-damascone were evaluated 
for % tail intensities and tail moments (± standard error of the mean, SEM); 125 mg/kg beta-
damascone group had 2.45 ± 0.13 % tail intensity and 0.27 ± 0.02 % tail moment; 250 mg/kg group 
had 2.99 ± 0.31 % tail intensity and 0.33 ± 0.03 tail moment; 500 mg/kg group had 2.93 ± 0.24 % tail 
intensity and 0.31 ± 0.03 tail moment that were similar to concurrent vehicle controls (tail intensity of 
2.67 ± 0.26 % and 0.29 ± 0.03 tail moment) and fell within the testing laboratories historic control 
range for vehicle controls (0.3 - 8.15 % tail intensity and 0.04 - 0.81 tail moment). The Comet arm of 
this study confirms that beta-damascone did not induce DNA damage in the liver under the conditions 
of this study (Beevers, 2013c). 
In a satellite study the slides from the duodenum tissue samples collected in the above study (Beevers, 
2013c) were analysed for Comet tailing effects (Beevers, 2013b). Duodenum cells of rats dosed with 
beta-damascone were evaluated for % tail intensities and tail moments (± standard error of the mean, 
SEM); 125 mg/kg beta-damascone group had 2.01 ± 0.43 % tail intensity and 0.32 ± 0.03 % tail 
moment; 250 mg/kg group had 1.47 ± 0.15 % tail intensity and 0.16 ± 0.02 tail moment; 500 mg/kg 
group had 2.03 ± 0.19 % tail intensity and 0.19 ± 0.02 tail moment that were similar to concurrent 
vehicle controls (tail intensity of 2.24 ± 0.43 % and 0.23 ± 0.04 % tail moment) and fell within the 
testing laboratories historic control range for vehicle controls (0.3 - 8.15 % tail intensity and 0.04 -
 0.81 tail moment). The duodenum Comet arm of this study confirms that beta-damascone did not 
induce DNA damage in the duodenum under the conditions of this study. The vehicle control data 
were within historical control ranges (95 % reference range:  0.77 to 8.32 % for tail intensity and 0.08 
to 1.15 for tail moment) and the positive control induced a clear increase in DNA damage. The study 
was therefore confirmed as valid. There was no evidence of duodenum toxicity as would be suggested 
by increases in clouds or halo cells. 
The % tail intensity and tail moment at all dose levels were very similar to the concurrent vehicle 
control, thus confirming there is no test article-related DNA damage. The additional tissue sample 
analysis for comet tailing showed a negative result for this study (Beevers, 2013b). 
The results from the combined in vivo micronucleus induction study and Comet assay show that orally 
administered beta-damascone did not induce micronucleated erythrocytes in rat bone-marrow cells nor 
genotoxic events in liver and duodenum of rats. 
CONCLUSION 
FGE.213 concerned 26 substances, corresponding to subgroup 2.7 of FGE.19 (see Table 1). Twenty-
three of the substances are α,β-unsaturated alicyclic ketones [FL-no: 07.008, 07.010, 07.014, 07.041, 
07.047, 07.056, 07.057, 07.075, 07.076, 07.080, 07.083, 07.089, 07.108, 07.109, 07.117, 07.118, 
07.119, 07.120, 07.127, 07.136, 07.168, 07.200 and 07.224] and three are precursors for such ketones 
[FL-no: 02.106, 09.305 and 09.525]. 
For 11 substances [FL-no: 07.047, 07.056, 07.057, 07.075, 07.076, 07.080, 7.117, 07.118, 07.119, 
07.120 and 07.168] the Panel have ruled out concerns regarding genotoxicity in FGE.213  
In the present opinion FGE.213Rev1, new data have been evaluated for the representative of the 
remaining substances. More specifically, data for beta-ionone [FL-no: 07.008], beta-damascone [FL-
no: 07.083],  maltol [FL-no: 07.014], nootkatone [FL-no: 07.089] and 2,6,6-trimethylcyclohex-2-en-
1,4-dione  [FL-no: 07.109]. All these studies are fully compliant with current guidelines, and stand in 
contrast to earlier studies previously evaluated in FGE.213. Flavouring Group Evaluation 213, Revision 1
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The combined evidence from in vitro and in vivo genotoxicity data for the selected representative 
substances beta-ionone [FL-no: 07.008], beta-damascone [FL-no: 07.083], nootkatone [FL-no: 07.089] 
and 2,6,6-trimethylcyclohex-2-en-1,4-dione  [FL-no: 07.109] does not indicate a genotoxic potential. 
Therefore, these substances and the nine substances that they represent, being [FL-no: 02.106, 07.010, 
07.041, 07.108, 07.127, 07.136, 07.200, 07.224 and 09.305] could be evaluated through the procedure.  
For maltol [FL-no: 07.014] and maltyl isobutyrate [FL-no: 09.525], the Panel concluded that the 
concern for genotoxicity could not be ruled out.  
 Flavouring Group Evaluation 213, Revision 1
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SUMMARY OF SPECIFICATION FOR SUBSTANCES IN FGE.213REV1 (JECFA, 1998; JECFA, 2000; JECFA, 2005A; JECFA, 2005B; JECFA, 2009B) 
Table 2:   Specification Summary of the Substances in the FGE. 213Rev1 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a)
Solubility in  
ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
02.106 
392 
4-(2,2,6-Trimethyl-1-cyclohexenyl)but-
3-en-2-ol 
OH
 
3625 
 
22029-76-1 
Liquid 
C13H22O    
194.32 
 
 
107 (4 hPa) 
 
IR 
92 % 
1.499 
0.927-0.933 
07.008 
389 
beta-Ionone 
O
 
2595 
142 
14901-07-6 
Liquid 
C13H20O    
192.30 
Insoluble 
1 ml in 3 ml 70% 
alcohol  
239 
 
IR 
95 % 
1.517-1.522 
0.940-0.947 
07.010 
399 
Methyl-beta- ionone 
O
 
2712 
144 
127-43-5 
Liquid 
C14H22O    
206.33 
 
 
238-242 
 
IR 
88 % 
1.503-1.508 
0.930-0.935 
07.014 
1480 
Maltol 
O
O
OH
 
2656 
148 
118-71-8 
Solid 
C6H6O3 
126.11 
Very slightly soluble 
Soluble 
 
159-162 
NMR 
98 % 
n.a. 
n.a. 
07.041 
 
beta-Isomethylionone 
O
 
4151 
650 
79-89-0 
Solid 
C14H22O 
206.32 
 
Freely soluble 
334 
62 
 
95 % 
n.a. 
n.a. 
07.047 
1481 
Ethyl maltol 
O
O
OH
 
3487 
692 
4940-11-8 
Solid 
C7H8O3 
140.14 
Soluble 
Soluble 
 
89-93 
NMR 
99 % 
n.a. 
n.a. 
07.056 
418 
3-Methylcyclopentan-1,2-dione 
O
O
OH
O
 
2700 
758 
80-71-7 
Solid 
C6H8O2    
112.13 
1 g in 72 ml water  
1 g in 5 ml 90% 
alcohol  
 
104-108 
IR 
95 % 
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Table 2:   Specification Summary of the Substances in the FGE. 213Rev1 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a)
Solubility in  
ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
07.057 
419 
3-Ethylcyclopentan-1,2-dione 
O
O
OH
O 3152 
759 
21835-01-8 
Solid 
C7H10O2    
126.16 
Miscible 
 
78-80 (5 hPa) 
36-43 
IR 
90 % 
1.47-1.48 (25°) 
1.060-1.066 
07.075 
420 
3,4-Dimethylcyclopentan-1,2-dione 
O
O
OH
O
 
3268 
2234 
13494-06-9 
Solid 
C7H10O2    
126.16 
 
 
66 (1 hPa) 
68-72 
IR 
98 % 
 
 
07.076 
421 
3,5-Dimethylcyclopentan-1,2-dione 
O
O
OH
O 3269 
2235 
13494-07-0 
Solid 
C7H10O2   
126.16 
Insoluble 
 
 
87-93 
MS 
98 % 
 
 
07.080 
425 
3-Methylcyclohexan-1,2-dione 
O
O
O
OH
 
3305 
2311 
3008-43-3 
Solid 
C7H10O2    
126.16 
Insoluble 
 
69-72 (1 hPa) 
57-63 
IR 
98 % 
 
 
07.083 
384 
beta-Damascone 
O
 
3243 
2340 
23726-92-3 
Liquid 
C13H20O    
192.30 
 
1 ml in 10 ml 95%  
67-70 
 
IR 
90 % 
1.496-1.501 
0.934-0.942 (20°) 
07.089 
1398 
Nootkatone 
O
 
3166 
11164 
4674-50-4 
Liquid 
C15H22O 
218.35 
Slightly soluble 
Soluble 
73-103 (1 hPa) 
 
NMR 
93 % 
1.510-1.523 
1.003-1.032 
07.108 
387 
beta-Damascenone 
O
 
3420 
11197 
23696-85-7 
Liquid 
C13H18O 
190.28 
 
1 ml in 10 ml 95% 
alcohol  
60 
 
IR 
98 % 
1.508-1.514 
0.945-0.952 (20°) Flavouring Group Evaluation 213, Revision 1
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Table 2:   Specification Summary of the Substances in the FGE. 213Rev1 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a)
Solubility in  
ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
07.109 
1857 
2,6,6-Trimethylcyclohex-2-en-1,4-
dione 
O
O
 
3421 
11200 
1125-21-9 
Solid 
C9H12O2 
152.2 
Slightly soluble 
Soluble 
222 
23-28 
IR NMR 
98 % 
n.a. 
n.a. 
07.117 
422 
3-Ethyl-2-hydroxy-4-methylcyclopent-
2-en-1-one 
O
OH
O
O
 
3453 
11077 
42348-12-9 
Liquid 
C8H12O2    
140.18 
Slightly insoluble 
Miscible 
 
 
NMR 
99 % 
1.481-1.487 
1.055-1.061 
07.118 
423 
5-Ethyl-2-hydroxy-3-methylcyclopent-
2-en-1-one 
O
OH
O
O
3454 
11078 
53263-58-4 
Liquid 
C8H12O2   
140.18 
Slightly soluble 
Soluble 
 
 
NMR 
99 % 
1.478-1.484 
1.053-1.060 
07.119 
424 
2-Hydroxycyclohex-2-en-1-one 
O
OH
O
O
 
3458 
11046 
10316-66-2 
Solid 
C6H8O2   
112.13 
Soluble 
Soluble 
53 (3 hPa) 
35-38 
IR 
99.3 % 
 
 
07.120 
426 
2-Hydroxy-3,5,5-trimethylcyclohex-2-
en-1-one 
O
OH
O
O
 
3459 
11198 
4883-60-7 
Solid 
C9H14O2 
154.21 
Slightly soluble 
Soluble 
90-100 (20 hPa) 
88 
IR 
99 % 
 
 
07.127 
757 
p-Mentha-1,4(8)-dien-3-one 
O
 
3560 
11189 
491-09-8 
Liquid 
C10H14O 
150.22 
Insoluble 
Miscible 
233 
 
MS 
95 % 
1.472-1.478 
0.976-0.983 
07.136 
1405 
4,4a,5,6-Tetrahydro-7-
methylnapthalen-2(3H)-one 
O
 
3715 
 
34545-88-5 
Solid 
C11H14O 
162.23 
Insoluble 
Soluble 
n.a. 
36-37 
IR 
99 % 
n.a. 
n.a. Flavouring Group Evaluation 213, Revision 1
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Table 2:   Specification Summary of the Substances in the FGE. 213Rev1 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a)
Solubility in  
ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
07.168 
2038 
2-Hydroxypiperitone 
OH
O
O
O
 
4143 
 
490-03-9 
Solid 
C10H16O2 
168.24 
Slightly soluble 
Freely soluble 
233 
82 
NMR MS 
98 % 
n.a. 
n.a. 
07.200 
 
4-(2,5,6,6-Tetramethyl-1-
cyclohexenyl)but-3-en-2-one   
O
 
 
 
79-70-9 
Liquid 
C14H22O 
206.33 
Practically insoluble 
or insoluble 
Freely soluble 
108 (2 hPa) 
 
MS 
95 % 
1.515-1.521 
0.943-0.949 
07.224 
 
tr-1-(2,6,6-Trimethyl-1-cyclohexen-1-
yl)but-2-en-1-one 
O
 
3243 
2340 
23726-91-2 
 
 
 
 
 
 
 
 
90 % 
 
 
09.305 
1409 
beta-Ionyl acetate   
O
O
 
3844 
10702 
22030-19-9 
Liquid 
C15H24O2 
236.35 
Insoluble 
Soluble 
120 (3 hPa) 
 
NMR 
92 % 
1.474-1.484 
0.934-0.944 
09.525 
1482 
Maltyl isobutyrate 
O
O
O
O
 
3462 
10739 
65416-14-0 
Liquid 
C10H12O4 
196.20 
Insoluble 
Soluble 
100 (0.01 hPa) 
 
IR 
96 % 
1.493-1.501 
1.140-1.153 
16.044 
1574 
Piperitenone oxide   
O
O
 
4199 
10508 
35178-55-3 
Solid 
C10H14O2 
166.22 
Soluble 
Soluble 
 
25 
NMR MS 
95 % 
n.a. 
n.a. 
(a):  Solubility in water, if not otherwise stated. 
(b):  Solubility in 95 % ethanol, if not otherwise stated. 
(c):  At 1013.25 hPa, if not otherwise stated. 
(d):  At 20°C, if not otherwise stated. 
(e):  At 25°C, if not otherwise stated. Flavouring Group Evaluation 213, Revision 1
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SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (JECFA, 1999; JECFA, 2001; JECFA, 2006A; JECFA, 2006B; JECFA, 
2009A) 
Table 3:   Summary of Safety Evaluation Applying the Procedure 
FL-no 
JECFA-no 
EU Register name  Structural formula  MSDI 
(a) 
(μg/capita/
day) 
Class 
(b) 
Evaluation procedure path 
(c) 
Outcome on the 
named compound 
 (d) or (e) 
EFSA conclusion on the 
named compound 
(genotoxicity) 
 
02.106 
392 
4-(2,2,6-Trimethyl-1-
cyclohexenyl)but-3-en-2-ol 
OH
 
0.73 
0.1 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No EFSA 
consideration required. 
07.008 
389 
beta-Ionone 
O
 
130 
100 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No EFSA 
consideration required. 
 
07.010 
399 
Methyl-beta- ionone 
O
 
5.4 
0.2 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No EFSA 
consideration required. 
 
07.014 
1480 
Maltol 
O
O
OH
 
3060 
2898 
Class II 
A3: Intake above threshold, 
A4: Not endogenous,  
A5: Adequate NOAEL exists 
(d)  Evaluated in FGE.213Rev1, 
genotoxicity concern could not 
be ruled out.Additional data 
requested. 
07.041 
 
beta-Isomethylionone 
O
 
0.011 
 
 
Not evaluated by the JECFA 
  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Can be evaluated 
using the Procedure in 
FGE.12Rev5. Flavouring Group Evaluation 213, Revision 1
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Table 3:   Summary of Safety Evaluation Applying the Procedure 
FL-no 
JECFA-no 
EU Register name  Structural formula  MSDI 
(a) 
(μg/capita/
day) 
Class 
(b) 
Evaluation procedure path 
(c) 
Outcome on the 
named compound 
 (d) or (e) 
EFSA conclusion on the 
named compound 
(genotoxicity) 
 
07.047 
1481 
Ethyl maltol 
O
O
OH
 
1580 
6692 
Class II 
A3: Intake above threshold, 
A4: Not endogenous,  
A5: Adequate NOAEL exists 
(d)  Evaluated in FGE.213, 
genotoxicity concern could be 
ruled out. Can be evaluated 
using the Procedure in 
FGE.83Rev1. No safety concern 
at the estimated level of intake 
based on the MSDI approach. 
07.056 
418 
3-Methylcyclopentan-1,2-dione 
O
O
OH
O
 
570 
710 
Class II 
A3: Intake above threshold, 
A4: Not endogenous,  
A5: Adequate NOAEL exists 
(d)  Evaluated in FGE.213, 
genotoxicity concern could be 
ruled out.  Evaluated by JECFA 
before 2000. No EFSA 
consideration required. 
07.057 
419 
3-Ethylcyclopentan-1,2-dione 
O
O
O
O 32 
23 
Class II 
A3: Intake below threshold 
(d)  Evaluated in FGE.213, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No EFSA 
consideration required. 
07.075 
420 
3,4-Dimethylcyclopentan-1,2-
dione  O
O
OH
O 30 
2 
Class II 
A3: Intake below threshold 
(d)  Evaluated in FGE.213, 
genotoxicity concern could be 
ruled out.  Evaluated by JECFA 
before 2000. No EFSA 
consideration required. 
07.076 
421 
3,5-Dimethylcyclopentan-1,2-
dione  O
O
OH
O 35 
29 
Class II 
A3: Intake below threshold 
(d)  Evaluated in FGE.213, 
genotoxicity concern could be 
ruled out.  Evaluated by JECFA 
before 2000. No EFSA 
consideration required. 
07.080 
425 
3-Methylcyclohexan-1,2-dione 
O
O
O
OH
 
1.3 
8 
Class II 
A3: Intake below threshold 
(d)  Evaluated in FGE.213, 
genotoxicity concern could be 
ruled out.  Evaluated by JECFA 
before 2000. No EFSA 
consideration required.Flavouring Group Evaluation 213, Revision 1
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Table 3:   Summary of Safety Evaluation Applying the Procedure 
FL-no 
JECFA-no 
EU Register name  Structural formula  MSDI 
(a) 
(μg/capita/
day) 
Class 
(b) 
Evaluation procedure path 
(c) 
Outcome on the 
named compound 
 (d) or (e) 
EFSA conclusion on the 
named compound 
(genotoxicity) 
 
07.083 
384 
beta-Damascone 
O
 
37 
10 
Class I 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
(d)  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No EFSA 
consideration required. 
 
07.089 
1398 
Nootkatone 
O
 
130 
20 
Class II 
A3: Intake below threshold 
(d)  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Can be evaluated 
using the Procedure in 
FGE.87Rev2.  
07.108 
387 
beta-Damascenone 
O
 
73 
5 
Class I 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
(d)  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No EFSA 
consideration required. 
 
07.109 
1857 
2,6,6-Trimethylcyclohex-2-en-
1,4-dione 
O
O
 
50 
 
Class II 
No evaluation 
  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Can be evaluated 
using the Procedure in 
FGE.09Rev5.  
07.117 
422 
3-Ethyl-2-hydroxy-4-
methylcyclopent-2-en-1-one 
O
OH
O
O
 
ND 
0.17 
Class II 
A3: Intake below threshold 
(d)  Evaluated in FGE.213, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No EFSA 
consideration required. 
07.118 
423 
5-Ethyl-2-hydroxy-3-
methylcyclopent-2-en-1-one 
O
OH
O
O
ND 
0.38 
Class II 
A3: Intake below threshold 
(d)  Evaluated in FGE.213, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No EFSA 
consideration required. Flavouring Group Evaluation 213, Revision 1
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Table 3:   Summary of Safety Evaluation Applying the Procedure 
FL-no 
JECFA-no 
EU Register name  Structural formula  MSDI 
(a) 
(μg/capita/
day) 
Class 
(b) 
Evaluation procedure path 
(c) 
Outcome on the 
named compound 
 (d) or (e) 
EFSA conclusion on the 
named compound 
(genotoxicity) 
 
07.119 
424 
2-Hydroxycyclohex-2-en-1-one 
O
OH
O
O
 
0.049 
0.76 
Class II 
A3: Intake below threshold 
(d)  Evaluated in FGE.213, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No EFSA 
consideration required. 
07.120 
426 
2-Hydroxy-3,5,5-
trimethylcyclohex-2-en-1-one 
O
OH
O
O
1.2 
2 
Class II 
A3: Intake below threshold 
(d)  Evaluated in FGE.213, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No EFSA 
consideration required. 
07.127 
757 
p-Mentha-1,4(8)-dien-3-one 
O
 
0.012 
0.01 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
(d)  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Can be evaluated 
using the Procedure in 
FGE57Rev1.  
07.136 
1405 
4,4a,5,6-Tetrahydro-7-
methylnapthalen-2(3H)-one 
O
 
ND 
0.04 
Class II 
A3: Intake below threshold 
(d)  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Can be evaluated 
using the Procedure in 
FGE.87Rev2.  
07.168 
2038 
2-Hydroxypiperitone 
OH
O
O
O
 
0.0012 
 
Class III 
A3: Intake below threshold 
(d)  Evaluated in FGE.213, 
genotoxicity concern could be 
ruled out. Can be evaluated 
using the Procedure in 
FGE.11Rev2. No safety concern 
at the estimated level of intake 
based on the MSDI approach. 
07.200 
 
4-(2,5,6,6-Tetramethyl-1-
cyclohexenyl)but-3-en-2-one 
O
 
0.012 
 
Class I 
No evaluation 
  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Can be evaluated 
using the Procedure in 
FGE.12Rev5. Flavouring Group Evaluation 213, Revision 1
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Table 3:   Summary of Safety Evaluation Applying the Procedure 
FL-no 
JECFA-no 
EU Register name  Structural formula  MSDI 
(a) 
(μg/capita/
day) 
Class 
(b) 
Evaluation procedure path 
(c) 
Outcome on the 
named compound 
 (d) or (e) 
EFSA conclusion on the 
named compound 
(genotoxicity) 
 
07.224 
 
tr-1-(2,6,6-Trimethyl-1-
cyclohexen-1-yl)but-2-en-1-one 
O
 
100 
 
 
No evaluation 
  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Can be evaluated 
using the Procedure in 
FGE.12Rev5. 
09.305 
1409 
beta-Ionyl acetate 
O
O
 
ND 
9 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.213Rev1, 
genotoxicity concern could be 
ruled out. Can be evaluated 
using the Procedure in 
FGE.73Rev3. MSDI based on 
USA production figure. 
09.525 
1482 
Maltyl isobutyrate 
O
O
O
O
 
20 
38 
Class II 
A3: Intake below threshold 
(d)  Evaluated in FGE.213Rev1, 
genotoxicity concern could not 
be ruled out.Additional data are 
requested. 
16.044 
1574 
Piperitenone oxide 
O
O
 
0.012 
0.2 
Class III 
A3: Intake below threshold 
(d)  Evaluated in FGE.213, 
additional genotoxicity data 
required. The substance is not 
supported by the Industy any 
longer. No further evaluation. 
(a):  EU MSDI: Amount added to food as flavour in (kg / year) x 10E
9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita/day. 
(b):  Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(c):  Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d):  No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e):  Data must be available on the substance or closely related substances to perform a safety evaluation. 
 
 Flavouring Group Evaluation 213, Revision 1
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QSAR PREDICTIONS ON MUTAGENICITY IN FIVE MODELS FOR 22 KETONES FROM SUBGROUP 2.7 
Table 4:   QSAR Predictions on Mutagenicity for 22 Alicyclic Ketones from Subgroup 2.7 
FL-no 
JECFA-no 
EU Register name  Structural formula 
(a) ISS  Local  Model 
Ames Test 
TA100 
(b) 
 
MultiCASE 
Ames test 
(c) 
 
MultiCASE 
Mouse 
lymphoma test 
(d) 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
(e) 
MultiCASE 
Chromosomal 
aberration test in 
CHL 
(f) 
07.008 
389 
beta-Ionone 
O
 
NEG NEG NEG NEG EQU 
07.200 
 
4-(2,5,6,6-Tetramethyl-1-
cyclohexenyl)but-3-en-2-one  
O
 
NEG NEG NEG NEG EQU 
07.010 
399 
Methyl-beta- ionone 
O
 
NEG  NEG OD  OD EQU 
07.041 
 
beta-Isomethylionone 
O
 
NEG EQU NEG NEG NEG 
07.083 
384 
beta-Damascone 
O
 
OD NEG OD  OD EQU 
07.108 
387 
beta-Damascenone 
O
 
OD NEG OD  OD EQU 
07.109 
 
2,6,6-Trimethylcyclohex-2-en-1,4-
dione 
O
O
 
OD NEG OD NEG  EQU Flavouring Group Evaluation 213, Revision 1
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Table 4:   QSAR Predictions on Mutagenicity for 22 Alicyclic Ketones from Subgroup 2.7 
FL-no 
JECFA-no 
EU Register name  Structural formula 
(a) ISS  Local  Model 
Ames Test 
TA100 
(b) 
 
MultiCASE 
Ames test 
(c) 
 
MultiCASE 
Mouse 
lymphoma test 
(d) 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
(e) 
MultiCASE 
Chromosomal 
aberration test in 
CHL 
(f) 
07.117 
422 
3-Ethyl-2-hydroxy-4-
methylcyclopent-2-en-1-one 
O
OH
O
O
 
OD NEG  NEG OD NEG 
07.118 
423 
5-Ethyl-2-hydroxy-3-
methylcyclopent-2-en-1-one 
O
OH
O
O
OD  NEG NEG NEG NEG 
07.119 
424 
2-Hydroxycyclohex-2-en-1-one 
O
OH
O
O
 
OD  OD NEG OD NEG 
07.120 
426 
2-Hydroxy-3,5,5-trimethylcyclohex-
2-en-1-one 
O
OH
O
O
 
OD NEG  NEG OD NEG 
07.014 
1480 
Maltol 
O
O
OH
 
OD  OD NEG OD POS 
07.047 
1481 
Ethyl maltol 
O
O
OH
 
OD  OD NEG OD POS 
07.056 
418 
3-Methylcyclopentan-1,2-dione 
O
O
OH
O
 
OD NEG  NEG OD NEG Flavouring Group Evaluation 213, Revision 1
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Table 4:   QSAR Predictions on Mutagenicity for 22 Alicyclic Ketones from Subgroup 2.7 
FL-no 
JECFA-no 
EU Register name  Structural formula 
(a) ISS  Local  Model 
Ames Test 
TA100 
(b) 
 
MultiCASE 
Ames test 
(c) 
 
MultiCASE 
Mouse 
lymphoma test 
(d) 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
(e) 
MultiCASE 
Chromosomal 
aberration test in 
CHL 
(f) 
07.057 
419 
3-Ethylcyclopentan-1,2-dione 
O
O
O
O OD NEG  NEG OD NEG 
07.089 
1398 
Nootkatone 
O
 
OD NEG  NEG  NEG POS 
07.127 
757 
p-Mentha-1,4(8)-dien-3-one 
O
 
OD NEG OD NEG  NEG 
07.136 
1405 
4,4a,5,6-Tetrahydro-7-
methylnapthalen-2(3H)-one 
O
 
OD NEG  NEG  NEG OD 
07.168 
- 
2-Hydroxypiperitone 
OH
O
O
O
 
OD  NEG NEG NEG NEG 
07.075 
420 
3,4-Dimethylcyclopentan-1,2-dione 
O
O
OH
O
 
OD NEG  NEG OD NEG 
07.076 
421 
3,5-Dimethylcyclopentan-1,2-dione 
O
O
OH
O OD  NEG NEG NEG NEG Flavouring Group Evaluation 213, Revision 1
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Table 4:   QSAR Predictions on Mutagenicity for 22 Alicyclic Ketones from Subgroup 2.7 
FL-no 
JECFA-no 
EU Register name  Structural formula 
(a) ISS  Local  Model 
Ames Test 
TA100 
(b) 
 
MultiCASE 
Ames test 
(c) 
 
MultiCASE 
Mouse 
lymphoma test 
(d) 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
(e) 
MultiCASE 
Chromosomal 
aberration test in 
CHL 
(f) 
07.080 
425 
3-Methylcyclohexan-1,2-dione 
O
O
O
OH
 
OD NEG  NEG OD NEG 
(a): Structure group 2.7: α,β-unsaturated ketones. 
(b): Local model on aldehydes and ketones, Ames TA100. (NEG: Negative; POS: Positive; OD*: out of domain). 
(c): MultiCase Ames test (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
(d): MultiCase Mouse Lymphona test (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
(e): MultiCase Chromosomal aberration in CHO (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
(f): MultiCase Chromosomal aberration in CHL (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
* OD, out of applicability domain: not matching the range of conditions where a reliable prediction can be obtained in this model. These conditions may be physicochemical, structural, 
biological etc. Flavouring Group Evaluation 213, Revision 1
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GENOTOXICITY DATA (IN VITRO) CONSIDERED BY THE PANEL IN FGE.213 
Table 5:   Genotoxicity (in vitro) 
Chemical Name [FL-no]   Test System  Test Object   Concentration  Reported 
Result  
Reference   Comments 
(d)
beta-Ionone [07.008]  Gene 
mutation(preincubation) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
1-180 µg/plate        Negative 
(a)      (Mortelmans 
et al., 1986) 
 
Valid. 
Gene mutation  S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 mmol/plate          Negative 
(a)     (Florin et al., 
1980) 
 
Insufficient validity (spot test, 
not according to OECD 
guideline, methods and results 
insufficiently reported). 
3-Methylcyclopentan-1,2-
dione [07.056] 
Reverse mutation  S. typhimurium TA1535   10 000 µg/plate           Negative 
(b)  (Heck et al., 
1989) 
 
Validity cannot be evaluated 
(result not reported in detail). 
Unscheduled DNA   
synthesis 
Rat hepatocytes           500 µg/plate              Negative 
(b)  (Heck et al., 
1989) 
 
Validity cannot be evaluated 
(result not reported in detail). 
Maltol  [07.014]   Reverse Mutation  S. typhimurium TA100  4.44 μmol/plate (560 
μg/plate)
  
Negative 
(c) (Kim et al., 
1987) 
 
Insufficient validity (only one 
concentration was tested with 
only one bacterial strain without 
metabolic activation). The main 
purpose of the study was to 
investigate antimutagenic 
effects. 
Reverse Mutation  S. typhimurium TA98 and 
TA100 
Up to 3 mg/plate (3000 
μg/plate)
  
Positive 
(a) (Bjeldanes and 
Chew, 1979) 
 
Valid. 
Reverse Mutation  S. typhimurium TA92, 
TA98, TA100 and TA104 
1.5 to 11 μmol/plate (189 
to 1387 μg/plate) 
Negative  (Gava et al., 
1989) 
 
Limited validity (data not 
reported in detail). 
Reverse Mutation  S. typhimurium TA1535, 
TA98, TA100 and TA1537 
33 to 10 000 μg/plate Positive 
(b) (Mortelmans 
et al., 1986) 
 
Valid.  Flavouring Group Evaluation 213, Revision 1
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Reverse Mutation  S. typhimurium TA97 and 
TA102 
0.1, 0.5, 1, 5, or 10 
mg/plate (100, 500, 1000, 
5000, or 10 000 μg/plate) 
Weak Positive 
(a)   
(Fujita et al., 
1992) 
 
Result is considered equivocal. 
Limited validity (the use of only 
two strains is not according to 
OECD guideline). 
DNA Damage (SOS 
Chromotest) 
Escherichia coli PQ37  5 mM (631 μg/ml) Negative  (Ohshima  et 
al., 1989) 
 
The test system used is 
considered inappropriate, due to 
insufficient validity. 
Sister Chromatid 
Exchange 
Chinese hamster ovary cells  Up to 1.5 μmol/ml (12.6 
to 189 μg/ml)
  
Positive 
(c) (Gava et al., 
1989) 
 
Validity cannot be evaluated 
(insufficiently reported: number 
of cells analysed not reported. 
Statistical test used not 
reported). SCEs were reported 
as SCE per chromosome. Effect 
was less than twofold compared 
to control. 
Sister Chromatid 
Exchange 
Human lymphocytes  Up to 1.0 mM  (126.11 
μg/ml)
  
Positive  (Jansson et al., 
1986) 
 
Validity cannot be evaluated. 
Relevance of test system for the 
evaluation of genotoxicity 
uncertain. 
Ethyl maltol [07.047] Reverse  Mutation  S. typhimurium TA 1535, 
TA1537, TA1538, TA98 
and TA100 
5 concentrations up to 
cytotoxicity, or max. 
3600 µg/plate 
Negative 
(a)  (Wild et al., 
1983) 
 
Limited validity (result not 
reported in details, no TA102 or 
E. Coli). 
Reverse Mutation  S. typhimurium TA98 and 
TA100 
Up to 2 mg/plate (2000 
μg/plate) 
Positive 
(a) (Bjeldanes  and 
Chew, 1979) 
 
Valid. 
(a):  With and without metabolic activation 
(b):  With metabolic activation  
(c):  Without metabolic activation  
(d):  Validity of genotoxicity studies: 
 Valid 
  Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation) 
  Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system) 
  Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
 Flavouring Group Evaluation 213, Revision 1
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GENOTOXICITY DATA (IN VIVO) CONSIDERED BY THE PANEL IN FGE.213 
Table 6:   Genotoxicity (in vivo) 
Chemical Name [FL-
no]  
Test System  Test Object   Route  Dose  Result   Reference   Comments 
(a)
Maltol  [07.014]  Micronucleus formation  ddY Mouse bone 
marrow cells 
Intraperi
toneal 
125, 250, or 500 mg/kg  Positive  (Hayashi et al., 
1988) 
 
Valid. The induction of 
micronuclei was up to about 
10-fold compared to control. 
Sex-linked Recessive 
Lethal Mutation  
Drosophila 
melanogaster 
Feeding  6000 ppm (6000 μg/ml)  Equivocal  (Zimmering et al., 
1989) 
 
Limited validity (only one 
exposure level tested). Test 
system considered of limited 
relevance. 
Sex-linked Recessive 
Lethal Mutation  
Drosophila 
melanogaster 
Feed  10 000 ppm (10 000 μg/ml)  Negative  (Mason et al., 
1992) 
 
Valid, however, test system 
considered of limited 
relevance. 
Sex-linked Recessive 
Lethal Mutation  
Drosophila 
melanogaster 
Injection  0.2 – 0.3 μl, 10 000 ppm (10 
000 μg/ml) 
Negative  (Mason et al., 
1992) 
 
Valid, however, test system 
considered of limited 
relevance. 
Ethyl maltol [07.047]  Micronucleus formation  NMRI Mouse 
bone marrow 
cells 
Intraperi
toneal 
420, 700, or 980 mg/kg  Negative  (Wild et al., 1983) 
 
Limited validity (injected 
twice; only analysis at one 
time point; no PCE/NCE 
ratio reported). 
Micronucleus formation NMRI  Mouse 
bone marrow 
cells 
Intraperi
toneal. 
980 mg/kg  Negative  (Wild et al., 1983) 
 
Limited validity (single 
injection, analysis at three 
time points, no PCE/NCE 
ratio reported). 
Sex-linked Recessive 
Lethal Mutation (Basc test) 
Drosophila 
melanogaster 
Feed  14, 25 or 50 mM 
 
Negative  (Wild et al., 1983) 
 
Limited validity (limited 
reporting, test system 
considered of limited 
relevance). 
(a):  Validity of genotoxicity studies: 
 Valid. 
  Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
  Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate  test system). 
  Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). Flavouring Group Evaluation 213, Revision 1
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CARCINOGENICITY STUDIES CONSIDERED BY THE PANEL IN FGE.213 
Table 7:   Carcinogenicity Studies 
Chemical Name [FL-no]   Species; Sex 
No./Group 
Route   Dose levels  Duration  Results  Reference  Comments 
(a) 
Ethyl maltol [07.047]  Rats; Male, 
Female 
25/sex/group 
Diet  0, 50, 100 and 
200 mg/kg 
bw/day 
2 years  Males: No increase in 
tumour incidences 
Females: No increase in 
tumour incidences 
(Gralla et al., 1969) 
 
Valid. The study was performed 
before the introduction of OECD 
guidelines but is however considered 
valid.The NOAEL was 200 mg/kg 
bw/day,  the highest dose tested.  
 
3-Ethylcyclopentan-1,2-
dione [07.057] 
Rats; Male, 
Female 
50/sex/group 
Diet  0, 30, 80 and 200 
mg/kg bw/day 
2 years  Males: No increase in 
tumour incidences 
Females: No increase in 
tumour incidences 
(King et al., 1979a) 
 
Valid. The study was performed 
before the introduction of OECD 
guidelines but is however considered 
valid.The NOAEL was 200 mg/kg 
bw/day,  the highest dose tested.  
 
(a): Validity of genotoxicity studies: 
 Valid. 
  Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
  Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system). 
  Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). Flavouring Group Evaluation 213, Revision 1
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GENOTOXICITY DATA (IN VITRO) CONSIDERED BY THE PANEL IN FGE.213REV1 
Table 8:   Summary of Additional in vitro Genotoxicity Data for FGE.213Rev1 
Chemical Name 
[FL-no:] 
Test System 
in vitro  
Test Object   Concentrations of 
Substance and Test 
Conditions  
Result   Reference   Comments  
beta-Ionone [07.008] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reverse 
Mutation 
 
S. typhimurium TA98, 
TA100, TA102, 
TA1535 and TA1537  
0.32-5000 μg/plate 
[1,2] 
 
Negative 
 
 
Ballantyne, 
2011 
 
Evidence of toxicity was observed in all strains at 
1000 μg/plate and above in the absence and in the 
presence of S9-mix. Study design complied with 
current recommendations. Acceptable top 
concentration was achieved. 
 
S. typhimurium TA98, 
TA100, TA102, 
TA1535 and TA1537 
 
10.24-1000 μg/plate 
[2,4] or [3,5] 
Negative 
 
Evidence of toxicity was observed in all strains at 
1000 μg/plate in the absence and presence of S9-
mix, and in most cases these toxic effects also 
extended down to concentrations of 160 or 400 
μg/plate. Study design complied with current 
recommendations.  
 
  
Micronucleus 
Assay 
Human peripheral blood 
lymphocytes 
30-60 μg/ml [4,6] 
80-120 μg/ml [5,6] 
5-17.5 μg/ml [4,7] 
Negative  Stone, 2011a  The top concentrations induced 50-60 % toxicity. 
The MNBN cell frequencies in all treated cultures 
fell within the normal range. Study design 
complies with OECD Guideline 487. 
Maltol [07.014] Reverse 
Mutation 
S. typhimurium TA98, 
TA100 and TA102, 
TA1535 and TA1537 
 
 
0.32-5000 μg/plate 
[1,2] 
 
 
Negative Ballantyne, 
2012 
Evidence of toxicity was observed in TA102 at 
1000 and 5000 μg/plate in the absence of S9-mix 
and at 200 μg/plate and above in the presence of 
S9-mix. Study design complied with current 
recommendations. Acceptable top concentration 
was achieved. 
S. typhimurium TA98, 
TA100, TA1535 
and TA1537 
51.2-5000 μg/plate 
[2,4] or [3,5] 
Negative 
 
 
Toxicity was observed at 5000 μg/plate in strain 
TA100 only in the presence of S9-mix. Study 
design complied with current recommendations. 
Acceptable top concentration was achieved. Flavouring Group Evaluation 213, Revision 1
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Table 8:   Summary of Additional in vitro Genotoxicity Data for FGE.213Rev1 
Chemical Name 
[FL-no:] 
Test System 
in vitro  
Test Object   Concentrations of 
Substance and Test 
Conditions  
Result   Reference   Comments  
   S. typhimurium TA102 20.48-5000  μg/plate 
[2,4] or [3,5] 
Negative    Evidence of toxicity was observed at 5000 
μg/plate in the absence and presence of S9-mix. 
Study design complied with current 
recommendations. Acceptable top concentration 
was achieved. 
 Micronucleus 
Assay 
Human peripheral blood 
lymphocytes 
400-1262 μg/ml 
[4,6] 
400-1262 μg/ml 
[5,6] 
125-300 μg/ml [4,7] 
Equivocal 
 
Positive 
 
Negative 
Whitwell, 2012  The top concentrations in the 3+21 hours 
treatments in the absence and presence of S9-mix 
induced, respectively,  24% and 19% of toxicity. 
The top concentration in the 24+0 hours 
treatment in the absence of S9-mix induced 57 % 
toxicity. There was evidence of micronuclei 
induction when tested for 3+21 hours in the 
presence of S9-mix, while in absence of S9-mix 
the data were considered equivocal. However, no 
induction of micronuclei was observed in the 
continuous exposure test. Study design complies 
with OECD Guideline 487. 
 
beta-Damascone [07.083]  Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535, 
TA1537 and TA102 
 
0.32-5000 μg/plate 
[1,2] 
 
Negative 
 
Bowen, 2011b  Toxicity was observed at 1000 and/or 5000 
μg/plate across all strains in the absence and 
presence of S-9; no clear evidence of toxicity in 
TA100 in the presence of S9-mix. No statistically 
significant increase in revertant numbers was 
seen at any concentration, either in the presence 
or absence of S9-mix. 
S. typhimurium , 
 TA1535, TA1537 and 
TA102 
S. typhimurium TA98, 
TA100 
78.13-2500 μg/plate 
[2,4] or [3,5]  
 
156.3-5000 μg/plate 
[2,4] or [3,5] 
Negative  
 
 
Negative  
  Evidence of toxicity was observed at the highest 
three or four concentrations across all strains in 
the absence and presence of S9-mix. No 
statistically significant increase in revertant 
numbers was seen at any concentration, either in 
the presence or absence of S9-mix 
S. typhimurium TA98 
 
19.3-1250 μg/plate 
[3,5] 
Negative     Evidence of toxicity was observed at the highest 
four concentrations in strain TA98 in the 
presence of S9-mix. No statistically significant 
increase in revertant numbers was seen at any Flavouring Group Evaluation 213, Revision 1
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Table 8:   Summary of Additional in vitro Genotoxicity Data for FGE.213Rev1 
Chemical Name 
[FL-no:] 
Test System 
in vitro  
Test Object   Concentrations of 
Substance and Test 
Conditions  
Result   Reference   Comments  
concentration, in the presence of S9-mix. 
Micronucleus 
Assay 
Human peripheral blood 
lymphocytes 
8-22 μg/ml [6,4] 
12-18 μg/ml[6,5] 
6-9 μg/ml [7,4] 
Equivocal [6,4] 
Positive [6,5] 
Equivocal [7,4] 
Stone, 2012  Positive result was obtained in the 3+21 hour 
treatment in the presence of S9-mix. Study design 
complies with OECD Guideline 487. 
Nootkatone 
[07.089] 
 
Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535,  
TA1537 and TA102 
0.5-50 μg/plate [2,4] 
1.5.5-150 μg/plate [2,5] 
 
0.5-50 μg/plate [2,4] 
0.5-150 μg/plate [3,5] 
Negative  Marzin, 1998  Evidence of toxicity was observed at 50 μg/plate 
in all strains in the absence of S9-mix and at 150 
μg/plate in all strains in the presence of S9-mix. 
Study design complied with current 
recommendations. Acceptable top concentration 
was achieved. 
 Micronucleus 
Assay 
 
Human peripheral 
blood lymphocytes 
50-80 μg/ml [4,6] 
160-185 μg/ml [5,6] 
10-24 μg/ml [4,7] 
   Negative 
 
Stone, 2011b  The top concentrations in all parts of the study 
induced > 50 % toxicity. The MNBN cell 
frequencies in all treated cultures fell within the 
normal range. Study design complies with OECD 
Guideline 487. 
2,6,6-Trimethylcyclohex-
2-en-1,4-dione 
[07.109] 
Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535,  
TA1537 and TA102 
0.32-5000 μg/plate 
[1,2] 
 
Negative  Bowen, 2011a  Evidence of toxicity was observed at 1000 and /or 
5000 μg/plate in strains TA102 and TA1535 in 
the presence of S9-mix. Study design complied 
with current recommendations. Acceptable top 
concentration was achieved. 
     156.3-5000  μg/plate 
[2,4] or [3,5] 
Negative    Evidence of toxicity was observed in TA102 at 
2500 and 5000 μg/plate. Study design complied 
with current recommendations. Acceptable top 
concentration was achieved. 
 
 Micronucleus 
Assay 
Human peripheral 
blood lymphocytes 
500-1522 μg/ml [4,6] 
1000-1522 μg/ml [5,6] 
300-550 μg/ml [4,7] 
Negative  Lloyd, 2011  The top concentrations in the 3+21 hours in the 
absence and presence of S9-mix were 10 mM. 
The top concentration in the 24+0 hours in the 
absence of S9-mix induced 57 % toxicity. The 
MNBN cell frequencies in all treated cultures fell 
within the normal range. Study design complies 
with OECD Guideline 487. 
[1] With and without S-9 metabolic activation; [2] Plate incorporation method; [3] Pre-incubation method; [4] Without S-9 metabolic activation; [5] With S-9 metabolic activation; [6] 3-hour 
incubation with 21-hour recovery period; [7] 24-hour incubation with no recovery period Flavouring Group Evaluation 213, Revision 1
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GENOTOXICITY DATA (IN VIVO) CONSIDERED BY THE PANEL IN FGE.213REV1 
Table 9:   Summary of Additional in vivo Genotoxicity Data Submitted for FGE.213Rev1 
Name [FL-no]   Test System  Test Object   Route  Dose  Result   Reference   Comments 
 
Maltol [07.014]  Micronucleus assay  Han Wistar Rat; M  Gavage  70, 350, 700 
mg/kg bw/day 
[1] 
Inconclusive  Beevers, 2013a  The average MNPCE appearance 
frequency and ratio of PCE at all dose 
levels fell within concurrent and 
historical control ranges. However, 
evidence of animal exposure was 
inconclusive. The study was 
performed in compliance with OECD 
Guideline 474. 
  Comet assay  Han Wistar Rat; M  Gavage  Negative  Mean % tail intensity and mean tail 
moment were within historical control 
range at all test doses. The study was 
performed in compliance with 
recommendations of the Comet and 
IWGT workshop, Japanese Center for 
the Validation of Alternative Methods 
(JaCVAM) and current literature. 
beta-Damascone  
[07.083] 
Micronucleus assay  Han Wistar Rat; M  Gavage  125, 250 and 500 
mg/kg bw/day 
[1]  
Negative  Beevers, 2013b,c  The average MNPCE appearance 
frequency and ratio of PCE at all dose 
levels fell within concurrent and 
historical control ranges. The study 
was performed in compliance with 
OECD Guideline 474. 
Comet assay  Han Wistar Rat; M  Gavage  Negative   Mean % tail intensity and mean tail 
moment were within historical control 
range at all test doses. The study was 
performed in compliance with 
recommendations of the Comet and 
IWGT workshop, Japanese Center for 
the Validation of Alternative Methods 
(JaCVAM) and current literature. 
 
[1] Administered via gavage in 3 doses at times 0, 24 and 45 hours with sacrifice and harvest at 48 hours 
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ABBREVIATIONS 
BW   Body  Weight 
CAS    Chemical Abstract Service 
CEF    Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO    Chinese Hamster Ovary (cells) 
CHL    Chinese Hamster Lung (cells) 
CoE   Council  of  Europe 
EC   European  Commission 
EFSA    European Food Safety Authority 
EU   European  Union 
FAO    Food and Agriculture Organization 
FGE    Flavouring Group Evaluation  
FISH    Fluorescence In Situ Hybridisation  
FLAVIS (FL)  Flavour Information System (database) 
GLP   Good  Laboratory  Practice 
ID   Identity 
IOFI    International Organization of the Flavor Industry 
i.p.   intraperitoneal 
IR   Infrared  spectroscopy 
JECFA   The Joint FAO/WHO Expert Committee on Food Additives 
MNBN   MicroNucleated BiNucleate cells 
MNPCE  Micronucleated Polychromatic Erythrocytes 
MS   Mass  Spectrometry 
MSDI    Maximised Survey-derived Daily Intake 
MTD     Maximum Tolerated Dose 
NCE     NormoChromatic Erythrocytes 
NMR    Nuclear Magnetic Resonance 
No   Number 
NOEL    No Observed Effect Level 
NAOEL  No Observed Adverse Effect Level 
OECD    Organisation for Economic Co-operation and Development 
PCE   PolyChromatic  Erythrocytes 
(Q)SAR  (Quantitative) Structure Activity Relationship 
RI   Replication  Index 
SCF    Scientific Committee on Food 
WHO   World  Health  Organisation 